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ABSTRACT 
 
Background:  Combination antiretroviral therapy (cART) for all Human Immunodeficiency Virus (HIV) 
infected pregnant and lactating women and post-exposure prophylaxis for HIV-exposed infants 
prevents mother-to-child transmission of HIV and has been the standard of care in Cape Town, South 
Africa since May 2013.  Despite high uptake and good coverage, transmission still occurs. Early 
identification of HIV infection in infants and access to cART are key components in reduction of 
morbidity and mortality in HIV- infected infants.  Reasons for ongoing transmission include missed 
diagnosis of infection during pregnancy and the postpartum period, short maternal duration on cART 
and issues around retention in care. In addition, poor uptake of the early infant diagnosis 
opportunities and delayed access to cART for infants is well documented.  
 
This study aimed to describe the antenatal and postnatal prevention of Mother-to-Child transmission 
(pMTCT) history and current medical condition of HIV-infected children younger than 18 months of 
age admitted to Tygerberg Hospital over a 12-month period, as well as document the availability of 
clinical information for these patients through an assessment of the Road-to-Health booklet (RtHB), 
medical records and the National Health Laboratory Service (NHLS). 
 
Materials & Methods:  This was a prospectively enrolled descriptive study from February 2015 to 
January 2016 that documented the pMTCT , infant diagnosis and care cascade of hospitalized HIV 
infected children younger than 18 months with newly diagnosed or previously confirmed HIV.  Data 
on maternal HIV and pregnancy history, as well as child HIV-history and clinical status were collected 
and descriptive analysis performed. 
 
Results:  Sixty-three children were screened and 55 enrolled (6 declined; 2 unavailable for consent).  
The median age was 5.7 (IQR 3 - 12.5) months; 33 (60%) were male.  Forty-six children (83%) were 
identified as HIV-exposed at birth.  The majority, 31 (67%), of their mothers were aware of their HIV 
diagnosis prior to pregnancy.  However, only 20 (65%) attended antenatal care, with 7 (23%) 
interrupting cART initiated prior to pregnancy.  Twenty-three women (50%) began cART during 
pregnancy:  11/31 (35%) were known to be HIV-infected prior to pregnancy and 12/15 (80%) were 
diagnosed during pregnancy (p=0.4).  Of these 23 women, 10 (43%) were not retained in care:  6/11 
(55%) of previously diagnosed and 4/12 (33%) of women diagnosed with HIV in pregnancy (p=0.4). 
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Children with unknown HIV-exposure risk were older:  9.3 (IQR 5.9 – 12.8) vs 4.5 (IQR 2.2 – 12.6) 
months (p=0.167) for known risk.  Fifteen children (27%) were diagnosed in the neonatal period, 5/15 
(33%) during hospitalization at Tygerberg Hospital.  Children with known exposure risk were diagnosed 
at a median age of 1.8 (IQR 0.1 – 3.5) months versus 9.4 (IQR 6.6 -12.1) months in unknown risk 
children (p=0.001).  Children with unknown HIV-exposure risk had a median weight-for-age z-score of 
-3.4 (IQR -4.2 - -2.3) vs -2.4 (IQR -4.1 - -1.8), (p=0.228) and 8 (89%) had WHO stage 3 or 4 disease versus 
36 children (78%) with known risk (p=0.195). 
 
The median duration from HIV diagnosis to cART initiation was 8 (IQR 5 – 30) days in known-risk 
children; 15/46 (27%) successfully initiated cART prior to admission and remained in care.  At time of 
hospitalization 5 children (9%) had discontinued previously initiated cART. 
 
Seven children (13%) died in hospital, with 14/55 (25%) (13 with known risk) requiring intensive care 
admission.  The median hospitalization duration was 17 days, similar in those with known (23 [IQR 12 
– 30.5] days) vs unknown risk (15.5 [IQR 10 – 32.3] days) (p=0.67). 
 
Forty-six (96%) of the RtHBs of our cohort were available for review during their admission.  Seven of 
55 children (12.7%) were still in the neonatal service and had not yet been issued a RtHB.  Of the 39 
(98%, N=40) children whose mothers were identified antenatally, 7 (18%) had an age-appropriately 
completed HIV-related page.  Of the 31 children older than 6 weeks, HIV polymerase chain reaction 
(PCR) testing was documented in 19 (61%), but the result was only noted in 15 (79%).  Initiation of co-
trimoxazole at 6 weeks was documented in 15 (52%).  Of the 8 children identified after delivery and 
outside the pMTCT service, 7 (88%) had RtBHs available, with only 1 child (14%) having any 
documentation of antenatal or postpartum tests noted.  Age appropriate vaccinations were 
documented in 24 of 39 (62%) of antenatally diagnosed children and 5 of the 7 children identified 
postpartum. 
 
Conclusion:  We identified poor antenatal clinic attendance and cART-treatment interruption in 
women aware of their status prior to pregnancy as the driver of newly infected infants.  Despite HIV 
being diagnosed relatively early, mortality and morbidity were high.  Documentation of HIV in the 
RtHB was poorly completed by healthcare workers, with a possible impact on the care cascade.  Of 
significant concern was the low completion of infant vaccination, a further pointer to the health 
seeking behaviour of mothers. 
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Identifying women at risk of transmitting HIV to their infants will be challenging as they often do not 
engage with the health care system.  Further research exploring the reasons for this is needed.  When 
these women do attend routine services, they should be identified and more effort made to retain 
them, not only in the pMTCT cascade of care but also into the well child follow-up system. 
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OPSOMMING 
 
Agtergrond: Kombinasie antiretrovirale terapie (kART) vir alle HIV-geïnfekteerde swanger en 
lakterende vroue, sowel as post-blootstellingsprofilakse vir HIV-blootgestelde kinders voorkom 
moeder-na-kind oordrag van HIV.  Dit is reeds sedert Mei 2013 die standaard van sorg in Kaapstad, 
Suid-Afrika.  Ongeag hoë opname en goeie dekking, kom oordrag steeds voor.  Vroeë identifikasie van 
HIV infeksie in kinders en toegang tot kART is sleutelkomponente in die vermindering van morbiditeit 
en mortaliteit in HIV-geïnfekteerde kinders.  Redes vir volgehoue oordrag sluit infeksies wat tydens 
swangerskap en die postpartum periode gemis is, kort moederlike duur op kART en probleme rondom 
retensie in sorg, in.  Daarbenewens is swak gebruikmaak van diagnoseringsgeleenthede en vertraagde 
toegang tot kART goed gedokumenteer. 
 
Die doel van hierdie studie is om, deur die beskrywing van die profiel van jong geïnfekteerde 
gehospitaliseerde kinders, begrip vir die huidige risikofaktore vir oordrag te verbreed, mislukkings in 
die diagnostiese en sorg-paaie te identifiseer en die geassosieerde morbiditeit en mortaliteit te 
beskryf.  Dokumentasie van die probleme in die sorg-paaie is ook ondersoek deur die 
gesondheidsorgwerkers se notas in die “Road-to-Health” boekies (RtHB) te dokumenteer en die 
opname van roetine sorg te assesseer deur na die vaksinasie rekords in die RtHB te kyk. 
 
Materiale en Metodes:  Hierdie was ‘n prospektief beskrywende studie vanaf Februarie 2015 tot 
Januarie 2016 waarin die voorkoming van Moeder-tot-Kind oordrag (pMTCT), diagnosering van 
kinders en sorgkontinuum van gehospitaliseerde HIV-geïnfekteerde kinders jonger as 18 maande met 
nuut-gediagnoseerde of voorheen bevestigde HIV, gedokumenteer is.  Data van moederlike HIV en 
swangerskapsgeskiedenis, sowel as kind se HIV geskiedenis en kliniese status is versamel en 
beskrywend analiseer. 
 
Resultate: Drie-en-sestig kinders is gesif en 55 ingesluit (6 wys deelname af; 2 nie beskikbaar vir 
toestemming). Die gemiddelde ouderdom was 5.7 (IQR 3 – 12.5) maande; 33 (60%) was manlik.  Ses-
en-veertig is identifiseer as HIV-blootgestel met geboorte.  Die meerderheid, 31 (67%), van hulle 
moeders was bewus van hul HIV-diagnose voor swangerskap.  Ten spyte daarvan het slegs 20 (65%) 
voorgeboortelike sorg bygewoon en 7 (23%, N=31) ook kART wat voor swangerskap iniseer is, 
onderbreek.  Drie-en-twintig vroue (50%) het kART tydens swangerskap begin: 11/31 (35%) se 
positiewe HIV-status was reeds voor swangerskap bekend en 12/15 (80%) is gedurende swangerskap 
gediagnoseer (p=0.4).  Tien (43%) van hierdie 23 vroue is nie in sorg behou nie: 6/11 (55%) van 
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voorheen gediagnoseerde en 4/12 (33%) van vroue tydens swangerskap met HIV gediagnoseer 
(p=0.4). 
 
Kinders met ‘n onbekende HIV-blootstellingsrisiko was ouer:  9,3 (IQR 5.9 – 12.8) teenoor 4.5 (IQR 2.2 
– 12.6) maande vir bekende risiko (p=0.167).  Vyftien kinders (27%) is tydens die neonatale periode 
gediagnoseer, 5/15 (33%) gedurende hospitalisasie by Tygerberg Hospitaal.  Kinders met ‘n bekende 
blootstellingsrisiko is gediagnoseer teen ‘n gemiddelde ouderdom van 1.8 (IQR 0.1 – 3.5) maande 
teenoor 9.4 (IQR 6.6 – 12.1) maande in onbekende risiko kinders (p=0.001).  Kinders met onbekende 
HIV-blootstellingsrisiko se gemiddelde gewig-vir-ouderdom z-telling was -3.4 (IQR -4.2 tot -2.3) 
teenoor -2.4 (IQR -4.1 tot -1.8), (p=0.228) en 8 (89%) het WGO (Wêreld Gesondheidsorganisasie) 
stadium 3 of 4 siekte teenoor 36 kinders (78%) met bekende risiko (p=0.195). 
 
Die gemiddelde duur van HIV diagnose tot kART-inisiasie was 8 (IQR 5 – 30) dae in bekende-risiko 
kinders; 15/46(27%) het kART suksesvol inisieer voor toelating en het in sorg gebly.  Teen die tyd van 
hospitalisering het 5 (9%) kinders voorheen inisieerde kART gestaak. 
 
Sewe kinders (13%) is in die hospitaal dood, met 14/55 (25%) (13 met bekende risiko) wat opname in 
intensiewe sorg benodig het.  Die gemiddelde hospitalisasieduur was 17 dae, ooreenstemmend in die 
met bekende (23 [IQR 12 – 30.5] dae) teenoor onbekende risiko (15.5 [IQR 10 – 32.3] dae) (p=0.67). 
 
Ses-en-veertig (96%) RtHBs van die kohort was beskikbaar vir ondersoek gedurende toelating.  Sewe 
van 55 kinders (12.7%) was nog in die neonatale diens opgeneem en dus nog nie in besit van ‘n RtHB. 
Van die 39 (98%, N=40) kinders wie se moeders antenataal identifiseer is, het 7 (18%) ‘n 
ouderdomstoepaslik voltooide HIV-verwante bladsy gehad.  Van die 31 kinders ouer as 6 weke, was 
HIV PKR toetsing gedokumenteer in 19 (61%), maar resultate slegs aangedui in 15 (79%).  Inisiëring 
van co-trimoxazole op 6 weke was gedokumenteer in 15 (52%).  Van die 8 kinders wie postpartum en 
buite die pMTCT diens geïdentifiseer is, was 7 (88%) se RtBHs beskikbaar, met dokumentasie rakende 
antenatale of postpartum toetse slegs by 1 kind (14%) aangedui.  Ouderdomstoepaslike vaksinasies 
was by 24 van die 39 (62%) antenataal gediagnoseerde kinders en 5 van die 7, postpartum 
geïdentifiseer, gedokumenteer. 
 
Gevolgtrekking:  Hierdie studie identifiseer swak voorgeboortelike kliniekbywoning en onderbreking 
van kART-behandeling by vroue bewus van hul HIV-status voor swangeskap as die dryfveer van nuut-
geïnfekteerde kinders.  Ten spyte daarvan dat HIV relatief vroeg gediagnoseer is, was mobiditeit en 
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mortaliteit hoog.  Dokumentasie van HIV in die RtHB is swak voltooi deur gesondheidsorg werkers, 
met ‘n moontlike impak op die sorg-kontinuum.  Lae voltooiing van die kindervaksinasies was ‘n 
ernstige bekommernis en verdere aanduiding van die gesondheidsorg-soekende gedrag van die 
moeders. 
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DEFINITIONS 
  Source 
Adherence The extent to which a person’s behaviour – taking 
medication, following a diet and/or changing 
lifestyle – corresponds with agreed 
recommendations from a health worker. 
World Health 
Organization (WHO) 
ARV Antiretroviral (ARV) drugs refer to medicines used 
to treat HIV 
WHO 
ART Antiretroviral therapy (ART) refers to the use of a 
combination of three or more ARV drugs for treating 
HIV infection. ART involves lifelong treatment. 
Synonyms are combination ART and highly active 
ART. 
WHO 
Birth PCR HIV PCR done in the first 7 days of life (< 7 days) Own 
Child A person 1 to younger than 10 years of age WHO 
Continuum of HIV 
care 
A comprehensive package of HIV testing, 
prevention, treatment and care services provided 
for people at risk of acquiring HIV and people living 
with HIV and their families. 
WHO 
Early infant diagnosis HIV testing of infants born to HIV-infected women 
within the first two months of life to determine their 
HIV status and eligibility for antiretroviral treatment 
WHO 
Exclusive 
breastfeeding 
The infant receives only breast milk without any 
other liquids or solids, not even water, except for 
oral rehydration solution or drops or syrups of 
vitamins, minerals or medicines 
WHO 
HIV-exposed infant 
or child 
An infant or child born to a mother living with HIV 
until the infant or child is reliably excluded from 
being HIV infected. 
WHO 
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HIV-pages in RtHB 
age-appropriately 
completed  
HIV-related pages in the RtHB fully completed as per 
the HIV-exposure status, child age and step in the 
pMTCT process 
Own 
In care Previously initiated on and taking cART Own 
Infant Child below 1 year of age (365 completed days of 
life) 
WHO 
Known HIV-Exposure 
Risk 
Children born to mothers who were diagnosed HIV-
infected prior to or during the index pregnancy. 
Own 
Linkage A process of actions and activities that supports 
people testing for HIV and people diagnosed with 
HIV in engaging with prevention, treatment and 
care services as appropriate for their HIV status. For 
people with HIV, it refers to the period beginning 
with HIV diagnosis and ending with enrolment in 
care or treatment. 
WHO 
Maternal pMTCT 
CD4 count 
CD4 cell count during pregnancy and up to 2 months 
postpartum using the test closest to delivery, 
preferably antenatally. 
Own 
Maternal pMTCT 
viral load 
HIV viral load during pregnancy and up to 2 months 
postpartum, using the test result closest to time of 
delivery, preferably antenatally. 
Own 
Mixed feeding An infant younger than six months of age is given 
other liquids and/or foods together with breast 
milk. This could be water, other types of milk or any 
type of solid food. 
WHO 
Neonatal period From birth until 28 completed days of life WHO 
Neonate An infant 0–28 days old. WHO 
Not in care Initiated on and defaulted cART prior to admission Own 
Perinatal period From birth until 7 completed days after birth WHO 
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(WHO Definition: From 22 completed weeks of 
gestation until 7 completed days after birth) 
Postnatal 
transmission 
Transmission of HIV to an infant or child after birth. 
Most postnatal transmission is through the breast 
milk of a woman living with HIV, but this also 
includes accidental infection, such as through an 
infected needle or through child abuse 
WHO 
Postpartum period First 7 completed days after birth Own 
Prevention of 
mother-to-child 
transmission of HIV 
The use of ARV drugs to prevent the transmission of 
HIV from the mother during pregnancy and 
breastfeeding 
WHO 
Retention in HIV care A person living with HIV who is enrolled in HIV care 
routinely attends these services in accordance with 
the need. 
WHO 
Self-interruption of 
cART 
Interruption in taking of cART initiated by women 
themselves, not as per order of medical professional 
Own 
Undetectable/ lower 
than detectable limit 
HIV viral load 
HIV RNA less than 50 copies/ml ((arbitrary value of 
40 copies/ml used for statistical analysis) or log 1.2 
(based on cut-off values used by NHLS)) 
Own 
Unknown HIV-
Exposure Risk 
Children born to mothers who were not known to 
be HIV-infected prior to, or during the index 
pregnancy. 
Own 
Vertical transmission Transmission of HIV that occurs from a mother living 
with HIV to her infant. This may occur in utero, in 
the peripartum period or postnatally through 
breastfeeding. 
WHO 
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1. INTRODUCTION AND LITERATURE REVIEW  
 
Prevention of Mother-to-Child Transmission (pMTCT) has evolved markedly over the past 20 years:   
From Zidovudine-based recommendations studied in the Pediatric AIDS Clinical Trials Group (PACTG) 
Protocol 076 study in 1994 in resource rich countries (1) and short course antiretroviral therapy (ART) 
prophylaxis, including single-dose Nevirapine (sdNVP), in resource-limited settings in 2000(2),  to 
lifelong combination antiretroviral therapy (cART) for all pregnant and breastfeeding Human 
immunodeficiency virus (HIV) infected women, as well as at least 6 weeks of single or dual drug ART 
prophylaxis in all HIV-exposed infants irrespective of feeding choice as recommended by the World 
Health Organization (WHO) since  2015.(3) 
 
The Global Health Strategy on HIV 2016 -2021 aims to eliminate the public health threat the Acquired 
Immunodeficiency Syndrome (AIDS) epidemic poses by 2030.  Their 2020 targets include the reduction 
of new HIV infections to less than 500 000, with no new infections in infants; reduction of HIV-related 
deaths to less than 500 000; as well as the 90-90-90 targets in which 90% of people living with HIV will 
know their HIV status, 90% with HIV will have sustained access to antiretroviral treatment and 90% on 
treatment will have suppressed viral loads.(4,5)  In order to achieve these goals, unprecedented scale-
up of HIV programmes and policies are needed, especially in low-to-middle income countries, with 
sustained commitment and effort from local, national and global counterparts.   
 
With regards mother-to-child transmission, particular attention needs to be paid to the prevention of 
HIV infection in women of reproductive age and, if women are infected, subsequent strategies to 
strengthen the existing effective, but still porous, pathway of interventions to prevent vertical 
transmission of HIV to their children. 
 
In the 2017 Joint United Nations Programme on HIV/AIDS (UNAIDS) Data report, it is documented that 
in 2016, an estimated 2.1 million (1.7million – 2.6 million) children under 15 years of age were living 
with HIV.  Twenty-six percent of new HIV infections in eastern and southern Africa were attributed to 
young women (15 – 24 years of age; 10% of the population) and globally 160 000 (110 000 – 220 000) 
children were newly infected.(6)  Only 49% (42 – 55%) of children living with HIV were accessing 
antiretroviral treatment in 2015, and child AIDS-related deaths in 2016 tallied to 120 000 (79 000 – 
160 000).(6,7)  This highlights that, despite greater availability of and access to proven effective cART-
backboned pMTCT strategies, children are still becoming HIV-infected. 
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Young HIV-infected children are at high risk of increased morbidity and mortality.    In the absence of 
cART, HIV-related mortality peaks at 2-3 months of age in South Africa.(8)  The Children with HIV Early 
Antiretroviral Therapy (CHER) study (2005-2007) showed that early HIV diagnosis and early cART at 6 
to 9 weeks of age, reduced early infant mortality and HIV progression by 76% and  75% respectively, 
when compared to deferring cART until clinical or cluster of differentiation 4 (CD4) criteria were met.  
Many screened children could not be randomized  due to their advanced disease at a young age.(9)  A 
review of South African data collected between 2007 and 2010 at multiple sites in Cape town and at 
Chris Hani Baragwanath Academic Hospital in Soweto, found that 62% of 403 infants who initiated 
cART at median 8.4 weeks of age had advanced HIV disease (CD4 <25% or <1500 cells/mm3 or WHO 
Stage 3 or 4 disease).(10)  Early infant diagnosis (EID) and timely initiation of cART are needed to 
improve outcome. 
 
1.1 PMTCT IN SOUTH AFRICA 
 
1.2 million (1.1 million – 1.4 million) women of reproductive age were newly diagnosed with HIV 
infection in South Africa between 2009 and 2015.  This group carries the highest number of new 
infections  in  the 21 Sub-Saharan priority countries  of the UNAIDS Global Plan towards the elimination 
of new HIV infections among children by 2015 and keeping their mothers alive(Global Plan).(11)  
Despite this, through programmatic scale-up by national and local government in line with WHO 
Guidelines and in keeping with the Millennium Developmental Goals and subsequent Sustainable 
Developmental Goals, as well as the Global Plan, the country has managed to reduce new HIV 
infections in South Africa by 84%, expand maternal ART coverage to more than 90%, limit the vertical 
transmission rate to 2% (1.9-2.2%), as well as decrease paediatric AIDS-related deaths by 90% between 
2009 and 2015.(11) 
 
1.2 THE CURRENT PMTCT GUIDELINES 
 
The 2015/6 pMTCT guidelines of the World Health Organization, the South African National 
Department of Health and the Western Cape Department of Health are summarized in Table 1 below.   
  
Stellenbosch University  https://scholar.sun.ac.za
 3 
 
Table 1.1:  Summarized 2015/16 WHO, South African and Western Cape pMTCT Guidelines 
 WHO Consolidated Guidelines 
2nd Edition 2016(3) 
National Consolidated ART 
Guidelines April 2015(12) 
Western Cape Consolidated 
Guidelines for HIV Treatment 
Nov 2015(13) 
HIV Testing in Pregnant 
Women 
 First antenatal visit 
If Negative: 
- 3 monthly in 
pregnancy 
- At delivery 
- At 6-week EPI visit 
- 3 monthly while 
breastfeeding 
First antenatal visit 
If Negative: 
- 3 monthly in 
pregnancy 
- At delivery 
- At 6-week EPI visit 
- 3 monthly while 
breastfeeding 
Maternal ART initiation Lifelong ART Same day lifelong ART  Same day Lifelong ART 
HIV viral load (VL) monitoring  On ART: <2 weeks since 
pregnancy diagnosis 
< 1000: 6 months 
>1000: 1 month 
Newly Diagnosed: 
At 3 months, then as above 
On ART: <2 weeks since 
pregnancy diagnosis 
<400: 3 monthly 
400 – 1000:  
<28weeks: 3 months 
>28weeks: 1 month 
>1000: 
1 month +- 2nd line ART 
Infant Prophylaxis    
  Mother ART > 4weeks 
NVP 6 weeks 
Mother ART >12 weeks/VL 
<1000copies/ml 
NVP 6 weeks 
 High Risk at birth: 
Breastfeeding: 
NVP ≥12 weeks and 
AZT 6 weeks 
Not Breastfeeding: 
NVP and AZT 6 weeks 
Mother ART < 4 weeks 
NVP 12weeks 
High Risk at birth: 
Breastfeeding: 
NVP ≥12 weeks and 
AZT 6 weeks 
Not Breastfeeding: 
NVP and AZT 6 weeks 
  Maternal VL on Rx 
>1000copies/ml: 
NVP and AZT 6 weeks  
High Risk during breastfeeding: 
Maternal VL > 1000copies/ml 
NVP ≥ 12 weeks 
No ART/Newly diagnosed: 
NVP ≥12 weeks and AZT 6 
weeks 
Infant HIV Testing Timing Birth 
4-6 weeks 
9 months 
18 months 
Clinically indicated 
Birth 
10 weeks or 
18 weeks 
6 weeks after final breastfeed 
18 months 
Any time indicated 
Birth 
10 weeks or 
18 weeks 
9 months 
6 weeks after final breastfeed 
18 months 
Any time indicated 
Breastfeeding If authorities promote 
breastfeeding:  6 months 
exclusive breastfeeding, 
followed by breastfeeding with 
appropriate supplementary 
foods until 12 months of age or 
as long as feasible/desired 
6 months exclusively 
At least 1 year if uninfected 
If HIV-infected: 
Until 24 months 
6 months exclusively 
If HIV-uninfected: 
Until 12 months with 
appropriate supplementary 
feeds 
ART – Antiretroviral therapy, AZT – Zidovudine, HIV – Human immunodeficiency virus, NVP – Nevirapine, pMTCT – prevention of Mother-
to-Child transmission, VL – viral load 
 
The April 2015 National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission 
of HIV (pMTCT) and the Management of HIV in Children, Adolescents and Adults recommends that all 
pregnant and breastfeeding women who initially test HIV negative during pregnancy should be seen 
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as part of the pMTCT programme.  They should undergo HIV testing at 3 monthly intervals during 
pregnancy, at delivery, at the 6-week Extended Programme on Immunization (EPI) visit, as well as 3 
monthly throughout breastfeeding.  These recommendations were included as 4% of women in South 
Africa who initially test HIV negative in pregnancy, seroconvert during or after pregnancy.(12)   
 
The ages at which infants are tested have changed in the 2015 guidelines to assist with the early 
diagnosis of in-utero infected children at birth, as well as reduce the possibility of missing children 
whose diagnosis may be delayed by the use of postnatal antiretroviral prophylaxis during 
breastfeeding.  In the 2015 guidelines HIV-exposed infants are tested at birth, 10 or 18 weeks and 18 
months of age.  Infants who receive 6 weeks of Nevirapine prophylaxis can be tested at 10 weeks, 
whereas infants on the extended 12-week Nevirapine schedule should only be tested at least 4 weeks 
after cessation of prophylaxis, at 18 weeks of age.(12) 
 
1.3 THE PMTCT CASCADE 
 
The pMTCT cascade/continuum is an integration of the parallel-running maternal and infant 
intervention and follow-up pathways indispensable for the prevention of mother-to-child 
transmission of HIV.  This same-location integration, that encompasses family planning, antenatal and 
postpartum care, as well as child survival services, is expected to improve retention in care and 
adherence to treatment and follow-up, assist with combining maternal and infant care, and linking 
HIV-infected infants and children to treatment services.(14) See figure 1.1 
 
PMTCT Care Continuum: Pregnant & Breastfeeding Women 
PMTCT Care Continuum: Infants 
 
 
 
Figure 1.1:  Continuum of care for pregnant and breastfeeding women and their children(14) 
Adapted from Figure 1 from the IATT Option B/B+ M&E Framework 
Well child 
care
Linkage to care 
& lifelong 
treatment
Mom/Bab
y ARVs
Early 
Infant HIV 
testing
Retention 
& 
monitoring
Final HIV 
Test Result
HIV Testing ART/ARVs Adherence & Retention
Linkage to 
lifelong care & 
treatment
Mom/Baby 
ARVs
Early Infant 
HIV testing
Linkage to 
lifelong care & 
treatment
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The maternal arm of the pMTCT continuum involves:(14) 
• Maternal HIV testing 
• ART initiation 
• Retention in care and adherence with treatment (as measured by HIV viral load) 
• Linkage to lifelong treatment and care 
• Achieving suppression and maintaining that throughout breastfeeding 
 
The infant arm comprises of:(14) 
• Maternal and infant ART in the antenatal, peri-partum, post-partum period and for duration 
of breastfeeding 
• Early infant testing/ diagnosis 
• Linkage to lifelong treatment and care (if HIV-infected) 
• If HIV negative at initial testing 
o Retention in care and monitoring 
o Repeat and final HIV-testing 
o Well-child care and follow up if remains uninfected. 
 
Throughout the continuum of care women and children are at risk of falling off the pathway if the 
correct interventions and support systems are not in place.   Luzuriaga and Mofenson reviewed the 
mother-infant pMTCT continuum to highlight areas of concern and where further research and 
intervention are required.  Based on 2014 UNAIDS and WHO data in the 22 priority countries, they 
identified that only 44% of pregnant women tested for HIV, 73% of tested and infected women 
received antiretroviral treatment during pregnancy and 61% of HIV-infected women received and 
adhered to treatment during breastfeeding.  Forty-four percent of HIV-exposed infants received HIV 
testing at 4 to 8 weeks of age and only 32% of confirmed HIV-infected infants received cART.(15) 
 
In the following sections we will describe and discuss the gaps and barriers that lead to attrition of 
mothers and their children along the pMTCT cascade, as well as potential strategies to allay them.  
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1.3.1 MATERNAL PMTCT CASCADE 
1.3.1.1 Maternal HIV testing  
 
From 2009 to 2015 there were 4.5 million (3.8 million – 5.4 million) new HIV infections among women 
of reproductive age in the 21 Global Plan countries.(11)  This group remains a high-risk population for 
acquiring HIV.  WHO reported that in 2013 only 44% of pregnant women in the 21 priority countries, 
where 90% of the HIV-burden exists, accessed HIV testing.(15) 
 
1.3.1.2 Bypassing Antenatal Care 
 
Pregnancy is an ideal opportunity for identifying HIV-infection in women, but not all women utilize 
antenatal care (ANC).  This is the first major gap in identifying HIV-infected women, as women who do 
not access ANC bypass the pMTCT cascade.  Antenatal clinic attendance in Nigeria, for instance, is only 
58%(16), whereas skilled-provider antenatal care utilization in Ethiopia between 2006 and 2010 was 
only 34%.(17).  South Africa reported a 92.9 % first visit antenatal care attendance in 2014 (Western 
Cape - 85.3% coverage).(18) 
 
A systematic review of the pMTCT cascade in China between 2003 and 2011 indicated that the 8.7% 
non-ANC attenders increased the 2011 national mother-to-child transmission (MTCT) rate from 2.3% 
(IQR 1.4% - 3.8%) when only assessing the ANC and pMTCT programme, to 11.5% (IQR 8%-15.7%) 
when the non-ANC attenders were factored in.(19)  If lack of antenatal care and pMTCT can have such 
a marked effect in a low HIV prevalence country (<0.1% in pregnant women(19)), the impact on high 
burden countries with poorer ANC attendance is potentially devastating.   
 
Barker et al. demonstrated how women who bypass or drop out of the antenatal care system 
contributed 16.5 HIV-infected children per 100 HIV-infected mothers of the 19.5 per 100 total HIV 
prevalence among exposed infants in their study.  This was a 25% transmission rate.  Mothers who 
attended antenatal care contributed 3 HIV-infected children per 100 infected mothers at a 
transmission rate of 8%.  They emphasized that the desired impact of current prevention regimens 
would not be obtained until more than 90% of women successfully accessed and completed all steps 
in the pMTCT cascade.(20) 
 
Efforts to encourage formalized antenatal care attendance are of paramount importance if the 
elimination of vertical HIV transmission is ever to be achieved. 
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1.3.1.3 HIV testing during pregnancy and breastfeeding  
 
In women who attend antenatal care, the utilization of HIV testing as recommended in the pMTCT 
guidelines is paramount in detecting all HIV-infected women.   
 
The timing of accessing antenatal care is another important factor in achieving pMTCT success.  The 
earlier cART is initiated (preferably prior to a planned pregnancy, ensuring a mother with a supressed 
HIV viral load antenatally) the lesser the chance of vertical HIV transmission, even in breastfeeding 
women postpartum.  Data, however, shows poor levels of early booking, with only 53.9% of South 
African women having their first antenatal care visit prior to 20 weeks’ gestation.(21) 
 
A single HIV test during pregnancy is also not adequate.  Serial testing at multiple points, as 
recommended by the local and international guidelines, assist in identifying women who sero-convert 
during pregnancy.(3,12,13)  It is imperative to identify these women, as they contribute to a large 
portion of HIV-infected infants.  South African national data from August 2011 to March 2012 
indicated that the 3.3% of the HIV-infected mothers who sero-converted during pregnancy, were 
responsible for 26% of early infant HIV infections.(22) 
 
In 2014 the United Nations Children’s Fund (UNICEF) and WHO Interagency Task Team on the 
Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children (IATT) 
identified that in the 22 Global Plan priority countries (21 in Sub-Saharan Africa and India) only half of 
the women who attended antenatal care received HIV counselling, testing and results.  Countries of 
particular concern were Zambia (12%) and the Democratic Republic of the Congo (23%), Nigeria (44%), 
and Chad (45%).  Only 9 countries achieved the set target of >80% utilization of antenatal counselling, 
testing and results, with South Africa achieving a 94% uptake during this time.(23)  South African 
studies have, however, shown a decrease in HIV-testing in the pMTCT setting of 5.3 - 20.6% at a 
number of testing sites.(24) 
  
Reasons for poor pMTCT-HIV-test utilization are multi-factorial.  A 2013 Ethiopian study where overall 
HIV-test utilisation was 58.1%, indicated high perceived self-efficacy as a positive and low perceived 
net benefit as a negative predictor for HIV-testing.(25)  Barriers to testing may be psychosocial (lack 
of knowledge about HIV, fear of being HIV-infected, disinterest) or health system related (lack of 
counsellors or tests or overburdened services).(26) 
 
Stellenbosch University  https://scholar.sun.ac.za
 8 
 
After testing for HIV, it is important that HIV-infected women receive their HIV results in order to be 
started on cART and linked to care.  In the Western Cape we currently utilize rapid testing, a strategy 
that eliminates the problems associated with the non-receipt of results associated with formal 
laboratory testing.  Further research in this care stage is necessary, as very little data is available for 
the 22 priority countries at present.(15)   
 
As previously stated, 4% of women in South Africa who initially test HIV negative in pregnancy 
seroconvert during pregnancy and breastfeeding.(12)  The importance of HIV testing in all women of 
childbearing age, especially breastfeeding women in high prevalence settings, can therefore not be 
over-emphasized, as HIV transmission is higher in newly infected cART-naive, as well as undiagnosed 
women, due to high viral load levels.(2) 
 
Partner testing is also important, as sero-discordance is a major risk factor for horizontal HIV 
transmission.  Couples should be offered routine voluntary testing and counselling and encouraged 
and counselled regarding mutual disclosure.(3) 
 
1.3.1.4 Maternal cART for pMTCT  
 
Multiple studies, including the Kesho Bora and Promoting Maternal-Infant Survival Everywhere 
(PROMISE) trials, have been done since the start of the use of maternal cART in pMTCT, in order to 
review efficacy and safety in the prevention of HIV transmission from mother to child ante-, peri- and 
postpartum, as well as during breastfeeding.(27–29)  Combination ART has become the cornerstone 
in eradication of paediatric HIV, as proven by near-elimination of vertical transmission in North 
America and Europe (30), with rates of 1% in Europe(31) and 2% in the USA(32).  The WHO defines 
elimination of MTCT as less than 50 new HIV cases per 100,000 live births over at least a one year 
period, with a transmission rate of less than 5% in breastfeeding and less than 2% in non-breastfeeding 
populations.(33)  Elimination of MTCT has been confirmed by WHO in Cuba(34) in 2015, as well as 
Thailand(35), Belarus and Armenia in June 2016.(11) 
 
The 2013 WHO Guidelines for the use of antiretroviral therapy in all pregnant and breastfeeding HIV-
infected women (Option B+ and Option B in countries where programmatic difficulties made B+ 
unfeasible) was a paradigm shift in the prevention of mother-to-child transmission of HIV.  It marked 
the beginning of the use of antiretroviral treatment as a preventative modality to curb transmission 
from mother-to-child, but also between discordant status partners irrespective of the clinical or 
immunological status of the HIV-infected mother.(36) 
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The 2015 WHO Consolidated Guidelines took this a step further with the recommendation of lifelong 
cART for all pregnant women, including women up until 1 year postpartum, irrespective of maternal 
immune status or infant feeding choice.(3) 
 
Initiation of and access to sustained cART is the next hurdle in the pMTCT cascade.  In South Africa the 
loss of mothers between HIV testing and cART initiation is 22 – 50%.(24)  In 2014, 65% and 77% of 
pregnant women in the 22 high-burden pMTCT countries were receiving lifelong cART and cART to 
reduce MTCT respectively.  Coverage for MTCT cART has improved, with 10 countries reaching the 
80% target, but lifelong cART lags despite all countries but Ivory Coast, Ghana and Nigeria adopting 
WHO Option B+.  Only 4 countries (Namibia, South Africa, Tanzania and Uganda) reached the >80% 
targets and in 7 countries (Burundi, Cameroon, Chad, Ivory Coast, Democratic Republic of the Congo, 
Ghana and Nigeria) less than 40% of HIV-infected women accessed lifelong cART.(23) 
 
Barriers to the uptake of cART are multi-factorial and closely linked to all steps in the pMTCT 
continuum.  A 2013 systematic review of articles published between 2000 and 2012 identifying 
barriers to pMTCT in sub-Saharan Africa, highlighted the key barrier levels:  Individual, partner and 
community, and health system.(2)  Stigma was an important factor, present in all 3 tiers, and the major 
documented reason why women shied away from taking cART in pMTCT, closely seconded by fear of 
partner disclosure.  Individual level barriers included a lack of knowledge about HIV(37), as well as 
doubts about the efficacy and safety of antiretroviral treatment.  Psychological factors involved in the 
staged grief response to their new HIV-infected status and the subsequent life-long health implications 
were the main barriers noted.  Uptake of cART improves in circumstances where there are partner 
and community support.  Significant health system barriers were staff and medication shortage, as 
well as problems, including the financial and logistical, with facility access.(2,16,37,38) 
 
Research into adherence after same-day cART initiation shows conflicting results.(39,40)  In Malawi it 
was found that although same-day cART initiation at the HIV-testing-and-counselling centre in the 
antenatal period increased the total number of women initiated on cART, the 6 month retention in 
cART care was worse in this group (22% v 8%, p=0.001) than in women who were diagnosed and 
started on cART at a later stage.(40)  The main reasons noted for discontinuing cART were treatment 
side-effects and the lack of partner support.(38) 
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1.3.1.5 Duration of cART and viral load monitoring 
 
At least 2 to 3 months on cART are required/recommended in pregnancy to have optimal chance of 
viral load suppression at delivery and optimal reduction in MTCT.(41)  In recent years, the use of the 
integrase inhibitor, Raltegravir, has been studied and confirmed safe for use and effective in reducing 
HIV viral load in pregnancy, especially in cases where rapid decline in HIV viral load are needed or 
conventional drug combinations cannot be used.(42) 
 
There are however 2 distinct groups of women that  need to be catered for:  Firstly, the women who 
were diagnosed with HIV prior to pregnancy and are treatment experienced, and secondly, those who 
are newly diagnosed in pregnancy or known infected, but treatment naive.(41)  
 
 
 
 
Figure 1.2:  Algorithm for viral load monitoring in HIV-positive pregnant women(12) 
Adapted from Figure 6 in the 2015 National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV 
(pMTCT) and the Management of HIV in Children, Adolescents and Adults. 
 
It is important that women who are known to be infected have a baseline HIV viral load at first contact 
with the antenatal service in order to assess treatment efficacy.  Women who are suppressed are 
encouraged to continue treatment, whereas women who are not suppressed (HIV viral load > 1000 
copies/ml) are reviewed, counselled regarding adherence and followed up for repeat viral load testing 
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in 1 month’s time in order to assess for suppression and urgently switch to second-line treatment if 
the viral load is still not suppressed.(41)  Further research into the need for earlier switching is needed. 
 
Newly diagnosed HIV-infected women should receive same-day cART initiation (unless cART is 
contraindicated, in which case Zidovudine (AZT) should be initiated) and viral load testing should be 
done in 3 months to assess suppression.  If the HIV viral load is suppressed treatment must continue, 
but if it is >1000 copies/ml, counselling on adherence and repeat viral load testing in a month are 
needed.(41) 
 
Women who are not virally suppressed at delivery or during breastfeeding, should be switched to 
second line treatment if adherence is confirmed.  Other options include multi-antiretroviral treatment 
prophylaxis for infants, as well as prolonged duration of prophylactic treatment until after 
breastfeeding cessation.  Birth PCR testing of infants can assist in identifying in-utero infected children 
in this group.  2016 WHO guidelines recommend that women who are at risk of non-suppression 
should have a HIV viral load  test performed 4 weeks prior to delivery, so that appropriate pMTCT 
measures can be taken.(41) 
 
It is imperative that services for viral load testing should be upscaled in order to attain universal access 
to efficient viral load testing with a short turn-around time. 
 
1.3.1.6 Delivery 
 
Delivery outside of a healthcare institution is a further risk for vertical HIV transmission, non-
institutional delivery is often accompanied by further lapses along the pMTCT cascade, including non-
attendance of antenatal care.  It is also the last opportunity to identify HIV-infected women in 
pregnancy and initiate them and their infants on the appropriate multidrug antiretroviral prophylaxis. 
According to Statistics South Africa (Stats SA) 85% of South African women (88% of those living in the 
Western Cape) delivered at a health care facility/ were assisted by skilled health care personnel.(18)   
 
1.3.1.7 Interventions to Improve EID and Adherence 
 
The use of cART in a preventative and prophylactic capacity lead to multiple questions regarding the 
long-term implications, especially with regards to adherence, retention in care and eventual resistance 
and side effect patterns in ART-exposed HIV-infected and -exposed infants. 
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Data from the 2016 UNAIDS Global Plan report shows that despite marked improvement in pMTCT 
strategies the HIV transmission rate increased from 4.7% (4.2% - 5.3%) at six weeks to 8.9% (8% - 10%) 
at the end of breastfeeding, indicating a problem with non-adherence and loss to follow up, especially 
during breastfeeding.(11)  Available literature has showed that between 25 and 50% of women on 
cART at delivery may not adhere to care in the postpartum period.(43) 
 
Improved programmes to ensure and measure adherence in the postnatal and breastfeeding period 
are needed, especially on a national level.(11) 
 
Strategies incorporated to improve retention in care and ongoing adherence to treatment include, 
integration of pMTCT services into routine Maternal and Child Health (MCH) services whilst aiming to 
provide centralized holistic care.  The use of technological interventions, like cell phone text messages 
or reminder calls has shown limited improvement in the retention of mothers in care in the first one 
to three months postpartum.(43)  More in-depth research is required in this field. 
 
1.3.2 INFANT CASCADE 
1.3.2.1 Infant Prophylaxis 
 
A 2014 systematic review of 7 randomized control trials evaluating the effectiveness of antiretroviral 
interventions in breastfed infants in low-to-middle income countries found that longer duration of 
NVP infant prophylaxis (6 weeks) was superior to shorter course (single dose) prophylaxis, and that 
the vertical transmission increased again once prophylaxis was stopped if breastfeeding was 
continued.  Prolonged single drug prophylaxis was found preferential to prolonged dual drug (AZT and 
NVP) ART due to the serious side effect profile of AZT.(44)  Dual drug prophylaxis is, however, more 
effective than single drug prophylaxis in preventing mother-to-child transmission in high risk settings 
(including mother not on cART for > 12 weeks or not virally suppressed; mother newly diagnosed 
during labour / less than 72 hours after delivery; increased transmission risk during labour, including 
chorioamnionitis, spontaneous preterm labour and prolonged rupture of membranes > 18 hours 
(13)).(5)   
 
HIV-infected infants who received prolonged NVP prophylaxis were more likely to develop subsequent 
resistance to the drug.(44)  Antenatal exposure to AZT is associated with more anaemia in new-borns, 
but at 1 to 6 months of age there is no difference between infants who received infant AZT prophylaxis, 
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irrespective of antenatal AZT exposure status.(45)  Maternal cART initiated prior to pregnancy is 
associated with a statistically significant higher rate of preterm delivery.(46,47) 
 
Mothers who do not adhere to their own antiretroviral treatment are more likely to non-adhere with 
infant-prophylaxis.(2)  Interventions to identify these women, as well as support them (including 
strategies like peer-counsellors, community outreach groups and telephonic/messaging reminders) 
need to be put in place to minimize loss of their infants to diagnosis and future care. 
 
1.3.2.2 Feeding Choice 
 
The 2016 WHO recommendations for infant feeding concluded that exclusive breastfeeding in a virally 
suppressed mother on cART for the first 2 years of life is the ideal in low-to-middle income countries 
to minimize infant malnutrition, morbidity and mortality.  These guidelines have not yet been adopted 
in South Africa.(48,49) 
 
1.3.2.3 Timing of EID  
 
In 2015 only 54% of HIV-exposed infants in the 21 priority countries were tested for HIV within the 
recommended first 2 months of life.(7)  This is a disconcerting statistic as evidence shows the 
accelerated progression of HIV disease in untreated infants leading to 20% mortality by 3 months of 
age (50),  30% by one year of age, and nearly half by 2 years of age.(11) 
 
The CHER trial showed how the early initiation of cART, at a median age of 7 weeks, induced a 76% 
reduction in infant mortality, as well as 75% reduction in disease progression.  Programmatic 
schedules where infants received PCR testing at 6 weeks, results at the 10-week immunization visit 
and then required further time for parental preparation to initiate treatment by approximately 3 
months of age, resulted in missing the all-important early initiation cut-off to prevent and reduce 
infant morbidity and mortality, which peaked at 8 – 12 weeks of age.(10)  This necessitated the 
programmatic evolution to include the birth PCR, to identify and timely treat in-utero infected 
infants.(10,51) 
 
Birth PCR identifies antenatal HIV infection but not HIV-infections acquired in the postnatal and 
breastfeeding period.  Age-appropriate HIV testing needs to be done 6 – 12 weeks after cessation of 
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breastfeeding (See Figure 1.3) and at any other time clinically indicated, as breastfeeding can delay 
the diagnosis of HIV beyond 18 months.(5,12)  
 
Figure 1.3:  Algorithm for HIV testing in children younger than 18 months(12) 
Adapted from Figure 2 in the 2015 National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV 
(pMTCT) and the Management of HIV in Children, Adolescents and Adults. 
 
Limitations in successful EID are encountered on various levels.  Woldesenbet et al. documented that 
only 62% of known HIV-exposed infants had a documented exposure risk in the RtHB or mother who 
disclosed her status.  In mothers who self-reported their HIV-positive status, only 49% had a 
corroboratively completed infant RtHB and 35% of them acknowledged having no intention to request 
infant HIV-testing at their child’s 6-week immunization visit.  With the use of provider initiated 
counselling and testing (PICT), 99% of these children did, however, receive early HIV testing.(52) 
 
Despite EID services being available in more than 95% of all primary healthcare facilities, only 72% of 
immunization service providers were geared to offer PICT.  Furthermore, dependence on poorly 
completed handheld records, poor continuity and linkage between antenatal and postnatal care, and 
lack of accountability for tracing of HIV-infected women and their exposed infants perpetuated the 
loss of children to EID.(52) 
 
Improvement in EID can be attained by educating mothers about the importance and process of 
pMTCT and maternal treatment adherence, as well as addressing the issues around stigma and 
discrimination.  Provider-initiated HIV testing in children with undocumented and unexposed HIV-
status is imperative to discover children who fell through the pMTCT cracks.(52) 
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The 18-month mother-to-child transmission rate in South Africa in 2014 sat at 4.3% (IQR 3.7 – 5%), 
with the highest cumulative rate of HIV transmission (3.5%) and death (4% of the cumulative 6.3% 
mortality at 18 months) occurring in the first 6 months of life.(53)  These numbers only further confirm 
the need for effective follow-up of HIV-exposed, but birth uninfected children. 
 
1.4 HOSPITALIZATION AND DISEASE PROFILE 
 
HIV-infection in children often manifests with non-specific signs and symptoms that mimic common 
childhood illnesses.(54) 
 
HIV-Infected neonates and young infants present with nondescript pictures that do not follow the 
traditional WHO Clinical staging patterns.  Jeena et al. conducted a year-long prospective study on 
infants younger than 60 days of age in Durban in 2003/4.  HIV-infected infants required hospitalization 
in almost 13% of cases, and were more likely than HIV-exposed uninfected and HIV-unexposed infants 
to be diagnosed with pneumonia, sepsis and oral thrush.  3% of the infected infants died due to 
bronchopneumonia and disseminated candida infection. This study was done in a time of limited ART 
availability for pMTCT or treatment.(55) 
 
Pneumonia and oral thrush, associated with unexplained malnutrition, as well as repeat hospital 
admissions in children aged 12 - 18 months of age are highly indicative of HIV-infection.  All children 
presenting with these conditions who have not received HIV-testing, should receive urgent PICT.  
Opportunistic infections, like Mycobacterium tuberculosis (TB), Pneumocystis jiroveci (PJP) and 
cytomegalovirus (CMV) are common, associated with high mortality as indicated by post-mortem 
diagnosis, and should be aggressively diagnosed and appropriately treated.(54,56,57) 
 
The most common conditions for which older children access healthcare or require hospitalization in 
Cameroon, Nigeria and India are malnutrition, persistent fever, recurrent respiratory tract infections 
and chronic diarrhoea (longer than 1-month duration).(58) 
 
Pneumonia is the major cause of hospitalization and mortality for HIV-infected children younger than 
5 years of age.  Pathogens are commonly multiple, including bacterial, viral and opportunistic 
aetiologies.(59)  Influenza, Respiratory syncytial virus (RSV) and Human Metapneumovirus are the 
most virulent pathogens associated with severe acute respiratory tract infections (SARIs) in South 
Africa.(60) 
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Opportunistic infections are common in HIV-infected children.  A systematic review in children under 
18 years of age evaluating 14 opportunistic infections, showed that TB (30% when disseminated, 
pulmonary and extra-pulmonary disease were combined), bacterial pneumonia (25%) and 
oropharyngeal candidiasis (8%) were the most commonly occurring opportunistic infections in HIV-
infected children.  Initiation of cART effected the most significant reduction in the prevalence of 
Cryptosporidium diarrhoea, cerebral toxoplasmosis and extra-pulmonary TB.(61) 
 
1.4.1 Mortality 
 
The mortality in young HIV-infected children is high, with 2011 research by Abrams et al. in 
Johannesburg, South Africa, showing a 19.5% mortality at 6 months follow-up review in HIV-infected 
children younger than 2 years, who were newly diagnosed, but not yet started on treatment at 
enrolment.  Risk of death was quadrupled when children were diagnosed during hospitalisation, and 
mortality risk was increased by immunosuppression (CD4 % less than 20%) and malnutrition (Weight-
for-age z-score (WAZ-score) less than -2 SD).(62) 
 
Data also shows that antenatally infected infants progress more rapidly and are at higher risk of early 
death if left undiagnosed and untreated.(10) 
 
AIDS-related deaths in South Africa for children aged 0 – 4 years have decreased by 90% between 
2009 and 2015.   This achievement is largely due to the reduction in new paediatric HIV-infections 
through increased access to quality pMTCT services, improved access to paediatric HIV treatment and, 
thirdly, reduction in maternal AIDS-related mortality with subsequent ability of mothers to remain 
healthy, care for their children and ensure adherence to child cART treatment.(11)  
 
The 2012-2013 Saving Children Report, released by the South African Medical Research Council (MRC) 
Unit for Maternal and Infant Health Care Strategies on behalf of Child Healthcare Problem 
Identification Programme (Child PIP) in June 2016, indicates that for the mentioned period, of the 
hospitalized patients who died, 17.7% were known HIV-infected, 21.5% were HIV-exposed and 14% 
had an unknown HIV status.  Only 10.5% of children were noted to be on cART and 12.7% who were 
supposed to be on treatment, did not receive cART.  Almost 2000 deaths (17%) in that time-period 
were in children known to be HIV-infected, where 2405 (21.5%) were in HIV-exposed infants.  Even 
though 35.3% of children who died were HIV-negative, an unacceptably high proportion at almost 
25%, had an unknown HIV status.(63) 
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The main causes of death in hospitalized HIV-infected children were pneumonia (18%), septicaemia 
(17.2%) and acute diarrhoea or hypovolaemic shock (13.8%).  Combined TB disease (including 
pulmonary, central nervous system and disseminated disease) contributed to approximately 9.7% of 
deaths.  The nutritional state of HIV-infected children who died was worse than those of the other 
children, with 26.7% being severely malnourished, and 30% underweight for age.(63) 
 
The largest proportion of HIV-infected children died between the ages of 28 days and 1 year (37.4%).  
HIV-infected children’s deaths were 32.4% in 1 – 5-year olds and 25.8% in the 5 to 13-year age group.  
HIV-infected children who died were also more likely to require longer admissions, 21.3% with 
admissions of 8-14 days and 17.2% longer than 14 days.(63) 
 
Despite marked improvement in the effectiveness of and access to pMTCT services to assist in the 
elimination of vertical transmission of HIV from mother to child, an unacceptably high number of 
children are still becoming infected, experiencing morbidity and mortality associated with delayed 
diagnosis and treatment initiation, and dropping out of the system through poor adherence and 
retention in care.  It is absolutely imperative that we not only identify the holes and stumbling blocks 
in the HIV-diagnosis and treatment continuum, but that we actively further investigate and implement 
measures to ensure its optimal efficacy. 
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2. STUDY JUSTIFICATION  
 
The current pMTCT cascade with lifelong cART to pregnant women, in conjunction with infant 
prophylaxis, despite its two-decade evolution with theoretically sound vertical HIV-transmission 
eliminatory power, is still fraught with obstacles in practice, especially in resource-poor settings.  This 
study aimed to describe HIV-infected children younger than 18 months of age admitted to hospital.  
By describing their profile, we aimed to highlight problems in the pMTCT cascade, on a systemic and 
individual level, that should be addressed to assist with elimination of the mother-to-child 
transmission of HIV. 
 
2.1 GAPS IN THE LITERATURE 
 
Literature currently fails to adequately address certain aspects of the pMTCT cascade.  Areas of 
concern where research is required in resource limited settings are:  
• Rates of HIV testing in pregnant and breastfeeding women, especially in settings using rapid 
HIV assays 
• Adherence to treatment and retention in care of HIV-infected women (and their infected 
children) 
• The linking of mother-child pairs to postnatal, including HIV, care 
• Rates of infant testing at 9 months and at 6 weeks after cessation of breastfeeding   
 
2.2 RESEARCH QUESTION 
 
Our research question was multifaceted.  Firstly, what are the issues/obstacles resulting in the pMTCT 
cascade not being completed adequately at both the maternal and infant level in infants with 
confirmed HIV infection?  Secondly, how are the HIV-related pages in RtHBs being completed? 
 
2.3 AIMS OF THE STUDY 
 
1. To describe the antenatal and postnatal pMTCT history and current medical condition of HIV-
infected children younger than 18 months admitted to Tygerberg Hospital over a 12-month 
period. 
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2.  To document the availability of clinical information for these patients through an assessment 
of the RtHB, medical record review and accessing the laboratory database of the National 
Health Laboratory Service (NHLS). 
 
2.4 OBJECTIVES 
 
1. To describe the antenatal and postnatal care for HIV-exposed children, including 
o Maternal factors 
 Antenatal care attendance 
 Timing of HIV diagnosis 
 CD4 count and HIV viral load 
 Timing of initiation and duration of cART prior to delivery 
 Postpartum access to care 
o Child factors 
 Infant ART prophylaxis 
 Infant feeding 
 Early infant diagnosis (EID) / HIV testing 
 CD4 count and viral load 
 cART initiation 
 
2.  To review the clinical condition of HIV-infected young children admitted to hospital, including 
WAZ-score, CD4 staging, HIV viral load, admission diagnosis, as well as need for intensive care 
unit (ICU) admission and eventual outcome (discharge/death). 
3. To review the availability of relevant information in the pMTCT details section of the Road-to-
Health booklet (RtHB) and the in-patient notes, as well as the NHLS database and relevant clinic, 
maternal obstetric unit or community health centre notes and data. 
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3. METHODS AND METHODOLOGY 
3.1 STUDY SETTING 
 
Tygerberg Hospital is a combined secondary-tertiary hospital in the high HIV-prevalence setting of 
Cape Town, South Africa.  HIV prevalence in South Africa as a whole, as reported by the 2012 Human 
Sciences Research Council (HSRC) national survey was 12.2% (95% CI: 11.4–13.1%), with 2014 data 
from the UNAIDS Spectrum estimates, indicating a prevalence of 6.4% (95% CI: 5.3-7.9) for people of 
all ages in the Western Cape.(21)  Tygerberg Hospital services a population of over 2.6 million people 
in the Western Cape and contains the 319 beds of the Tygerberg Children’s Hospital, of which 18 are 
intensive care and 8 – 12 high care beds (this includes both neonatal and paediatric beds).  
 
3.2 STUDY DESIGN 
 
This study was a prospectively enrolled descriptive study, describing the pMTCT and clinical status of 
children admitted to Tygerberg Children’s Hospital younger than 18 completed months of age, who 
were newly or previously diagnosed as HIV-infected.  A non-random convenience sample of sequential 
patients admitted to the general and specialist paediatric service at Tygerberg Hospital from 9 
February 2015 and 31 January 2016 was used. 
 
3.3 STUDY POPULATION, INCLUSION AND EXCLUSION CRITERIA  
 
All HIV-infected children younger than 18 completed months of age, admitted to the Tygerberg 
Hospital paediatric service over the one-year study period were eligible for inclusion in the study.  
 
Inclusion criteria 
• HIV-infected children:  2 x PCR (DNA/RNA) positive 
• Younger than 18 completed months of age 
 
Exclusion criteria: 
• No informed consent. 
• Child older than 18 months of age during current admission. 
• HIV not confirmed as per case definition. 
• Previous enrolment in this study during a prior Tygerberg Hospital admission. 
• Discharge or death prior to enrolment 
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3.4 DATA COLLECTION AND MANAGEMENT 
 
All mother-child pairs eligible for enrolment were given a sequential unique case identifier (starting 
from 001).  Participants who consented kept their initial identifier number for the rest of the study. 
 
Data were obtained from maternal interview, review of child clinical notes, including electronic copies 
on the Tygerberg Hospital Enterprise Content Management system (TBH ECM), the RtHB, as well as 
the NHLS, that provided access to HIV-PCR, CD4 cell count and HIV-viral load laboratory results.  In 
cases where relevant data were not immediately available at the time of enrolment, later review of 
laboratory results and clinical notes were done.  Missing maternal cART and pMTCT data were 
telephonically obtained from local clinics/ community health centres, as well as the NHLS and TBH 
ECM, where possible. 
 
All data were collected onto a study-specific case report form (CRF). See Appendix 4.  From the CRF 
the data was transcribed onto a spreadsheet (Microsoft Excel®). 
 
3.5 DATA ANALYSIS AND STATISTICAL METHODS 
 
Basic descriptive statistics were done with Stata® 14, Excel® 2016 and Statistics Open for All (SOFA) 
Version 1.4.6, with further statistical analysis in Stata® 14. 
 
Continuous data were not normally distributed and therefore reported as medians and Interquartile 
ranges.  Categorical data were tabulated. 
 
Statistical testing (where permitted) was done using Chi-Square and Fisher Exact testing.  A p-value of 
<0.05 was taken as being statistically significant. 
 
In instances where sample number was insufficient for accurate statistical testing the p-values were 
noted, but only descriptive statistics were used to avoid biased reporting. 
 
3.6 ETHICAL CONSIDERATIONS 
 
The study was approved by the Health Research Ethics Committee (HREC) of the University of 
Stellenbosch (Protocol Number S14-09-183). See Appendix 2. 
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Informed consent for participation in the study was obtained from all mothers.  See Appendix 3.  In 
cases where consent was declined, the mother-infant pair was not included in the study. 
 
Strict confidentiality was maintained.  Only the principle investigator collected data and no personal 
identifiers were entered on the CRFs. 
 
The CRFs, along with the accompanying consent form, were kept in a secure case in possession of the 
principle investigator.  A secure copy of the unique study identifiers and patient details was kept on 
the principle investigator’s password-protected computer.  Data were stored in protected databases.   
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4. RESULTS:  
4.1 PARTICIPANTS AND SCREENING PROCESS 
 
Seventy eligible participants were identified and 65 were screened. (Figure 4.1) 
 
 
 
Figure 4.1:  Screening and enrolment of mother-infant pairs 
 
Fifty-five mother-infant pairs were enrolled:  46 (84%) women had known HIV transmission risk, with 
31/46 (67%) known to be HIV-infected prior to the latest pregnancy and 15/46 (33%) newly diagnosed 
as HIV-infected during the latest pregnancy.  Nine women (16%) were diagnosed with HIV in the 
postnatal period after provider-initiated testing identified their children as infected (Figure 4.1).
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Table 4.1:  Maternal diagnosis and cART during pregnancy and the postpartum period 
 All Mothers 
(N = 55) 
Known HIV-Exposure Risk (N=46) 
Unknown HIV-Exposure  
Risk 
(N=9) 
P  Total Known HIV-Exposure 
Risk  
(N=46) 
Mother Diagnosed Prior to 
Pregnancy  
(N=31) 
Mother Diagnosed during 
pregnancy  
(N=15) 
P  
 N/n  N/n  N/n  N/n   N/n   
Age at delivery median(IQR)  28 (24-31)  28 (24.8 - 31)  28 (25 - 31)  27 (24 - 32) 0.716  25 (23 - 31) 0.724 
Gravida median(IQR)  2 (2-4)  2 (2-4)  3 (2-4)  2 (1-4) 0.445  2 (2-3) 0.945 
Antenatal care attended n(%)  42 (76)  35 (76)  20 (65)  15 (100) 0.008  7 (78) 0.913 
First antenatal visit ≥ 28 weeks n(%)  5 (12)  5 (14)  3 (15)  2 (13)   0  
First antenatal visit <14 weeks n(%)  6 (14)  3 (9)  2 (10)  1 (7)   3 (33)  
cART initiated prior to pregnancy and in care     7 (15)  7 (23)  0 (0)     
cART initiated prior to pregnancy and not in Care n(%)    7 (15)  7 (23)  0 (0)     
cART started in Pregnancy (new & previous defaulted) n(%)     23 (50)  11 (35)  12 (80)     
No cART in pregnancy n(%)    9 (20)  6 (19)  3 (20)     
CD4 count during pregnancy in cells/mm3  median(IQR)   41* 280 (176 – 363) 26* 270 (176 – 365) 15 281 (182 – 361) 0.685    
            CD4 <200 cells/mm3 n(%)    14 (34)  9 (35)  5 (33)     
            CD4 <500 cells/mm3 n(%)    36 (88)  23 (88)  13 (87)     
HIV Viral load log during pregnancy  median(IQR)   19* 3.7 (2.8 – 4.8) 14* 4.1 (2.9 - 4.8) 5* 2.7 (2.4 – 4.3) 0.392    
            Prior cART, in Care   4 3.6 (2.7 – 5) 4 3.6 (2.7 - 5)       
           cART started in Pregnancy   10 3.3 (2.8 – 4.8) 7 3.6 (2.8 – 5.1) 3 2.7 (2.2 – 4.8)     
           No cART   5 4.1 (3.2 – 4.7) 3 4.6 (4.1 – 4.8) 2 3.2 (2.7 – 3.7)     
Mode of delivery  n(%) 55  46  31  15   9   
               Vaginal deliveries in health facility n(%)  33 (60)  25 (54)  19 (61)  6 (40)   8 (89)  
              Caesarean section n(%)  16 (29)  15 (33)  8 (26)  7 (44)   1 (11)  
               Birth before arrival n(%)  6 (11)  6 (13)  4 (13)  2 (13)   0  
Mothers on cART at delivery  n(%)     25 (54)   13 (42)  12 (80)  0.015    
Time on cART at delivery in months  median(IQR)   25* 2 (1 - 7.5) 13* 2 (0.5 – 48) 12*  0.5 (1 – 3) 0.176    
Maternal cART status enrolment n(%) 55  46   31   15   0.583 9   
            Prior cART, in Care  22 (40)  22 (48)  13 (42)  9 (60)     
            Prior cART, not in Care  15 (27)  15 (33)  11 (35)  4 (27)     
            No cART  14 (26)  7 (15)  5 (16)  2 (13)   7 (78)  
            cART initiated during child admission  4 (7)  2 (4)  2 (6)  0   2 (22)  
Latest CD4 count in cells/mm3 median(IQR  52* 291 (178 – 413) 46 281 (167–394) 31 280 (166 - 384) 15 281 (182 - 443) 0.631 6* 340 (307-816) 0.165 
Latest HIV Viral Load log median (IQR) 31* 4.2 (2 - 4.9) 28* 3.9 (1.9 – 4.9) 21* 4.1 (1.9 – 5) 7* 3.7 (LDL – 4.8) 0.770 3* 4.8 (4.3 – 4.9) 0.349 
Latest HIV Viral load LDL  n(%)   28* 6 (21) 21* 4 (19) 7* 2 (29) 0.306    
cART – combination antiretroviral therapy, CD4 – Cluster of differentiation 4, HIV – Human immunodeficiency virus, IQR – interquartile range, LDL – lower than detectable limit 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
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4.2 MATERNAL DIAGNOSIS AND CARE 
4.2.1 Timing of maternal HIV diagnosis, attending antenatal care and antiretroviral therapy use 
4.2.1.1 Mothers identified prior to and during pregnancy 
 
Forty-six women were known to be HIV-infected during the pregnancy of the enrolled child:  31 (67%) 
were diagnosed prior to the pregnancy and 15 (33%) during pregnancy.  The median maternal age at 
delivery was 28 years (Interquartile range (IQR) 25 – 31).  The median gravidity for women diagnosed 
with HIV prior to pregnancy was 3 (IQR 2-4) and during pregnancy 2 (IQR 1-4), p = 0.445.  Seventy-six 
percent (35/46) of women with HIV-infection diagnosed prior to or during pregnancy attended 
antenatal care.  The majority 27/35 (77%) presented for antenatal between 14 and 28 weeks 
gestation, but 5/35 (14%) booked after 28 weeks’ gestation (Table 4.1). 
 
Women who initiated or reinitiated cART during pregnancy (23/46, 50%) had a median duration on 
cART of 1 month (IQR 0 – 3, n=19), while those previously initiated on cART were on treatment for a 
median of 48 months (IQR 8 – 72, n=6), (table 4.1). One woman received only intrapartum prophylaxis 
(stat and 3 hourly AZT, sdNVP + Tenofovir/Emtricitabine (TDF/FTC)). 
  
Due to the fact that we used verbal report of any antenatal antiretroviral use, we did not ascertain 
whether monotherapy with AZT were provided to women who did not initiate cART.  We also did not 
explore the reasons for the non-initiation of therapy.  We documented one clear case of health 
systems failure:  In this case, a woman who tested negative early in pregnancy had a CD4 count done 
when she presented with preterm labour to a local facility, we assume this was in response to a 
reactive point of care test, however this was not clearly documented.  No further tests were 
performed and no maternal or infant ART was provided.  At 3 months of age the infant presented with 
severe pneumonia requiring Paediatric intensive care unit (PICU) admission and was diagnosed with 
HIV infection. 
 
Mothers who previously defaulted cART were less likely to restart cART in the current pregnancy 
(p=0.01).  Knowledge of partner status, disclosure and family support as reported by women at 
enrolment, were not predictive of cART not being initiated. (Table 4.2) 
 
Infants of mothers not on cART at conception were delivered at late preterm gestation of 36 weeks 
(IQR 33-40):  Where mothers initiated cART during pregnancy, the median birth gestation was 35 
weeks (IQR 33-38) versus 40 weeks (IQR 34 – 40) where mothers did not initiate cART, p=0.068 (Table 
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4.2).  Just over half (54%) of women known with HIV delivered vaginally at a healthcare facility and 
13% delivered at home.  Approximately a third (30%) had caesarean sections. (Table 4.1) 
 
4.2.1.2 Mothers identified after pregnancy  
 
The 9 women diagnosed postpartum had a median age of 25 years (IQR 23 -  31) and gravidity of 2 
(IQR 1-4).  Seven (78%) attended antenatal care, all initiating antenatal care prior to 28 weeks of 
gestation (Table 4.1).  Infants were delivered at a median gestation of 39 weeks (IQR 34 - 40) (Table 
4.4), and all except one were born via vaginal delivery at a healthcare facility. (Table 4.1) 
 
4.2.2 Maternal Disease Severity (Table 4.1) 
 
Women were severely immune suppressed in pregnancy:  The median CD4 cell count was 280 
cells/mm3 (IQR 176 – 363, N = 41), with 34% (14/41) having CD4 cell counts less than 200 cells/mm3; 
43% (10/23) of those started on cART during pregnancy. (Table 4.4) 
 
An antenatal HIV viral load was known for 13 (28%) women; an additional 4 (9%) women had viral load 
tests within the 7 days after delivery.  The median absolute HIV viral load log during pMTCT was 3.7 
(2.8 – 4.8).  None of the women with HIV viral loads available during pregnancy were virally suppressed 
(HIV viral load <50 copies/ml). (Table 4.1) 
 
Three women were treated for tuberculosis during pregnancy and 3 women were diagnosed with 
syphilis.  All 3 infants exposed to tuberculosis received Isoniazide (INH) prophylaxis as indicated.  None 
of the women with syphilis (all diagnosed HIV-infected prior to pregnancy) completed treatment:  1 
(33%) was partially treated and 2 (67%) received no treatment.  Two (67%) of their children received 
treatment postnatally. 
 
At enrolment the median CD4 count remained low, 280 cells/mm3 (IQR 167 – 394).  Six of the 28 (21%) 
women with known HIV-transmission risk with an available HIV viral load at child admission, were 
virally suppressed (HIV VL LDL):  4/21 (19%) of women diagnosed prior to pregnancy and 2/7 (29%) 
diagnosed during pregnancy.  All these women were on cART at some point, but 2 women diagnosed 
prior to pregnancy defaulted treatment subsequent to the suppressed viral load. (Table 4.1) 
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4.2.3 Maternal Retention in care (Table 4.1, 4.2 and 4.3) 
 
Of the 31 women known with HIV prior to pregnancy, 14 (46%) were on cART prior to pregnancy but 
only 7 were in care at the time of pregnancy.  Although 76% (35/46) of women known with HIV 
attended antenatal care, only two (29%, N=7) women who defaulted previously initiated cART 
attended antenatal clinic.  At delivery, 42% (13/31) of women previously known to be HIV-infected 
and 80% (12/15) of women diagnosed during pregnancy were on lifelong cART. (Table 4.1) 
 
However, at the time of enrolment only 22/46 (48%) were on cART and in care.  Fifteen (33%) were 
previously on cART, but had defaulted treatment:  11/31 (35%) diagnosed prior to pregnancy, and 
4/15 (27%) diagnosed during pregnancy.  Four women interrupted cART during pregnancy, all known 
with HIV prior to pregnancy, and 12 women interrupted cART in the postpartum period, 5 (38%) 
diagnosed during pregnancy.  
Table 4.2: Comparing mothers who initiated antiretroviral therapy in pregnancy and those who did not  
 
Not on cART at conception 
(N=39) 
Started or restarted cART 
in pregnancy 
(N=23) 
cART not started 
(N=16) 
P 
N/n  N/n  N/n   
Age median(IQR)  28 (24 – 32)  28 (23 – 33)  27 (25 – 32) 0.987 
Antenatal care attended n(%)  29 (74)  20 (87)  9 (56) 0.031 
Booked after 28 weeks gestation n(%) 29* 5 (17) 20* 4 (20) 9* 1 (11) 0.558 
Previously defaulted cART n(%)  9 (23)  2 (9)  7 (44) 0.011 
Gestation at delivery  median(IQR) 38* 36 (33 – 40)  35 (33 – 38)  40 (34 – 40) 0.068 
Gravidity  median(IQR)  3 (2 – 4)  2 (2 – 4)  3 (2 – 4) 0.361 
CD4 count in cells/mm3  median(IQR) 35* 280 (176 – 361)  240 (176 – 350) 12* 308 (221 – 453) 0.175 
WHO immunosuppression classification:  n(%)   
          Mild:  350 – 499 cells/mm3 
 
6 (17)  4 (17)  2 (17) 
 
          Advanced:  200 – 349 cells/mm3  11 (31)  7 (30)  4 (33)  
          Severe  < 200 cells/mm3  13 (37)  10 (44)  3 (25)  
Viral load log in pMTCT median(IQR) 15* 3.7 (2.8 – 4.8) 10* 3.3 (2.8 – 4.8) 5* 4.1 (3.2 – 4.7) 0.807 
Tuberculosis in pregnancy  n(%)  2 (5)  2 (9)  0 0.226 
Syphilis in pregnancy  n(%)  3 (8)  2 (9)  1 (6) 0.778 
Same site cART and antenatal care n(%) 25* 18 (72) 20* 16 (80) 5* 2 (40) 0.075 
Single  n(%) 38* 18 (47)  13 (57) 15* 5 (33) 0.162 
Grant n(%) 33* 15 (46) 18* 8 (44) 15* 7 (47) 0.898 
Contraception  n(%) 35* 16 (46) 20* 11 (55) 15* 5 (33) 0.245 
Partner HIV status known  n(%) 38* 19 (50) 23* 12 (52) 15* 7 (47) 0.640 
Child status disclosed to partner/family n(%) 38* 25 (66) 23* 15 (65) 15* 10 (67) 0.927 
Partner involved in child HIV care n(%) 26* 16 (62) 14* 9 (64) 12* 7 (58) 0.756 
Family involved in child treatment  n(%) 25* 16 (64) 14* 10 (71) 11* 6 (55) 0.383 
cART – combination antiretroviral therapy, CD4 – Clusters of differentiation 4, HIV – Human immunodeficiency virus, IQR – Interquartile range, pMTCT – prevention of 
Mother-to-Child transmission, WHO – World Health Organisation 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
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Table 4.3:  Comparing mothers who interrupted cART prior to enrolment with those who did not  
 
All started on cART 
(N=37) 
cART prior, in Care 
(N=22, 59%) 
Defaulted prior cART 
(N=15, 41%) 
p 
N/n  N/n  N/n   
Time on cART between booking and delivery in months  
median(IQR) 
25* 2 (1 – 7.5) 17* 3 (1 – 18) 8* 0.5 (0 – 2.5) 0.030 
Gestation at initial visit 30*  21*  9*  0.082 
          < 14 weeks  2 (7)  2 (10)  0  
          14 to <28 weeks  24 (80)  18 (86)  6 (67)  
          ≥ 28 weeks  4 (13)  1 (5)  3 (33)  
Gestation at delivery in weeks  median(IQR) 36* 37 (34.5 – 40) 21* 37 (35 – 38.5)  37 (34 – 40) 0.710 
Gravidity  median(IQR)  2 (2 – 4)  2 (2 – 3)  3 (1 – 4) 0.285 
Defaulted prior to pregnancy n(%)  5 (14)  2 (9)  3 (20) 0.341 
Started cART in pregnancy for first time n(%)  20 (54)  11 (50)  9 (60) 0.549 
Started cART prior to pregnancy, incl. defaulters n(%)  15 (41)  9 (41)  6 (40) 0.956 
Started postpartum n(%)  2 (5)  2 (9)  0 0.230 
Tuberculosis in pregnancy n(%)  3 (8)  2 (9)  1 (7) 0.791 
Syphilis in pregnancy  n(%)  2 (5)  0  2 (13) 0.078 
Home delivery n(%)  5 (14)  4 (18)  1 (7) 0.314 
Partner HIV status known  n(%)  18 (49)  10 (46)  8 (53) 0.374 
Child status disclosed to partner/family n(%)  26 (70)  14 (64)  12 (80) 0.285 
Partner involved in child treatment n(%) 26* 15 (58) 15* 7 (47) 11* 8 (72) 0.184 
Family involved in child treatment  n(%) 25* 17 (68) 15* 10 (67) 10* 7 (70) 0.861 
Latest maternal CD4 count in cells/mm3  median(IQR)   261 (162 – 375)  262 (149 – 443)  261 (166 – 356) 0.901 
Latest maternal HIV viral load log  median(IQR) 23* 2.9 (LDL – 5) 14* 2.8 (LDL – 4.4) 9* 5 (1.5 – 5.1) 0.282 
HIV viral load LDL 23* 6 (26) 14* 4 (29) 9* 2 (33)  
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, IQR – Interquartile range, LDL – Lower than detectable limit 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
 
4.2.4 Maternal Sociodemographic context 
 
Fifty-two percent of women (28/54) were single.  Only 13% (7/54) were employed and 50% (24/48) 
accessed money through the social grant system. 
  
Knowledge of partner status was poor, with less than half of women (47%, 21/47) knowing their 
partner’s HIV status and the child’s HIV status only being disclosed in 67% of cases (30/45).  Family 
was involved in the HIV treatment of the child in 68% (21/31) and partners in 56% (18/32) of cases. 
 
Fifty-nine percent (17/29) of previously HIV-infected women and 46% (6/13) of index pregnancy 
diagnosed women used contraception postnatally.  
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4.3 PMTCT, DIAGNOSIS, CLINICAL FEATURES AND ACCESS TO CART OF THE CHILDREN 
4.3.1 PMTCT continuation (Table 4.4) 
 
Sixty percent of the children (33/55) were male with a median birthweight of 2525g (IQR 2025-2890) 
and a median gestation at birth of 37 weeks (IQR 34-40).  The median birthweight of known exposure-
risk children was 2440g (IQR 2025-2920) versus 2595g (IQR 2180 - 2830) in those with unknown HIV-
exposure risk, p=0.972.  Birth gestation was 37 weeks (IQR 34-40) in known exposure-risk versus 39 
weeks (34-40) in unknown exposure-risk children, p=0.364.  Thirteen infants (87%, N=15), whose 
mothers were diagnosed HIV-infected during the index pregnancy, breastfed exclusively during the 
first six months, while 16/31 infants (52%) whose mothers were HIV-infected prior to pregnancy opted 
to exclusively formula feed in the first 6 months.  Children with unknown HIV-exposure risk breastfed 
exclusively during the first 6 months of life in 87% (8/9) of cases. 
 
4.3.2 HIV diagnosis (Table 4.4, 4.5) 
 
The majority of infants had in utero or early postpartum transmission, with 59% (24/41) having their 
first positive PCR prior to completing postpartum ART prophylaxis.  A third of children with known HIV-
exposure (15/46) had the first positive PCR in the first 28 days of life.  Ten (22%) were diagnosed at 
their community health centre/clinic at a median age of 50 days (IQR 42 – 93), while the rest were 
diagnosed in hospital during acute illness or in the neonatal period, at 54 days (IQR 3-108).  Infants of 
mothers identified prior to pregnancy were diagnosed at a median age of 56 days (IQR 19-134), while 
infants of mothers diagnosed during pregnancy were 46 days (IQR 0-94) old at diagnosis, p=0.27. 
 
Seven children (15%) were only diagnosed after 6 months of age (180 days) of age, 4 of these children 
(57%) with a previously documented non-reactive HIV-PCR.  One child had 3 negative HIV-PCRs prior 
to the reactive test. 
 
Children with unknown HIV-exposure risk were diagnosed HIV-infected at a median age of 286 days 
(200-369). 
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Table 4.4:  Infant HIV prevention, feeding choice, HIV diagnosis and time to initiation of therapy  
 
All Children 
(N=55) 
Known HIV-Exposure Risk 
(N=46) 
Unknown HIV-Exposure 
Risk 
(N=9) p 
N/n  N/n  N/n  
Male  n(%)  33 (60)  31 (67)  2 (22) 0.011 
Birthweight in gram median(IQR) 54* 2525 (2025-2890) 45* 2440 (2025 – 2920)  2595 (2180 - 2830) 0.972 
Gestational age at birth in weeks median(IQR) 53* 37 (34-40) 44* 37 (34 – 40)  39 (34 - 40) 0.364 
Feeding choice during initial 6 months  n(%)        0.060 
          Exclusive breastfeeding  29 (53)  22 (48)  7 (78) 0.721 
          Exclusive formula feeding  18 (33)  18 (39)  1 (11)  
ARV prophylaxis  n(%)   45* 42 (93)    
Age at HIV diagnosis in days  median(IQR)  59 (6-184)  54 (3 – 106)  285 (200-369) 0.001 
Age at cART initiation in days median (IQR)  107 (24 – 205)  76 (20 – 178)  286 (190 – 392) <0.001 
Time from HIV diagnosis to cART initiation in days  
median(IQR)  8 (5-27)  9 (5 – 30) 
 5 (2-8) 0.039 
Time from HIV Diagnosis to admission in days   
median(IQR) 45* 47 (1.5-187.5) 40* 56.5 (3 – 285.5) 5* 1 (0 – 14) 0.039 
Children on ART prior to admission n(%)     20 (43)    
Time from cART initiation to admission in days 
median(IQR) those still on cART   15* 105 (29 – 360)    
Age at start (all previously initiated) median(IQR)   20* 70 (14 – 110)    
First CD4 %   median(IQR) 49* 23.7 (17.9 – 36.3) 42* 23.4 (17.7 – 36.5) 7* 24.7 (20.5 – 33.3) 0.842 
WHO CD4% Immunodeficiency Staging    n(%) 49*   42*   7*    
       Mild immunodeficiency  
           (≤11 months: 30-35%; 12-35 months: 25-30%)  6 (12)  4 (10)  2 (29)  
       Advanced Immunodeficiency 
           (≤11 months: 25-29%; 12-35months: 20-24%)  5 (11)  3 (7)  2 (29)  
       Severe immunodeficiency 
           (≤11 months: <25%; 12-35 months: <20%)  23 (47)  20 (48)  3 (43)  
First HIV Viral load log median(IQR) 50* 5.7 (4.2 – 6.4) 42* 5.5 (4.2 – 6.3) 8* 6.3 (5 – 6.7) 0.161 
cART status during admission  n(%)          0.034 
     Newly Diagnosed  25 (45)  17 (37)  8 (89)  
     Prior cART, In Care  15 (27)  15 (33)  0 (0)  
     Prior cART, Not in Care  5 (9)  5 (11)  0 (0)  
     Prior Diagnosis, No cART  10 (18)  9 (20)  1 (11)  
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, IQR – Interquartile range, WHO – World Health Organization 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
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4.3.3 Clinical disease severity and causes of hospitalization at enrolment (Table 4.7, 4.8) 
 
The median age at hospital admission during enrolment was 174 days (IQR 90 – 381):   Children with 
known exposure were younger (median age 138 days) than children without antenatal identification 
(median 282 days), p=<0.001. 
  
Children had advanced HIV:  80% (44/55) had WHO Stage 3 and 4 clinical disease.  Malnutrition was 
prevalent, the median weight-for-age z-scores was -2.4 (IQR -4.1 to -1.8) in the known exposure-risk 
group and -3.4 (IQR -4.2 to -2.3) in the unknown risk group, p = 0.228.  Weight-for-height could not be 
assessed due to poor recording of height.  
 
Almost half (47%, 23/49) of children had severe immunosuppression according to WHO 
immunodeficiency classification, with 69% (34/49) having some degree of immunosuppression.   
 
The 3 most common admission diagnoses were pneumonia (45%, 25/55), gastroenteritis (36%, 20/55) 
and severe acute malnutrition (40%, 22/55).  Ten of the 55 children (18%) were diagnosed with 
tuberculosis (6 cases were pulmonary and 4 disseminated TB). 
 
Eighty-seven blood cultures were done in 37 children of which 10 were positive (we did not 
differentiate hospital and community acquired organisms).  No cases of pneumococcal disease were 
confirmed.  Forty-three respiratory viral panels were performed on 22 patients resulting in 31 positive 
results in 17 different patients.  Cytomegalovirus (CMV) was common (24 isolates in 12 patients), and 
25 CMV viral loads were done.  Five patients had an initial CMV viral load log > 5, indicating significant 
viraemia that could be indicative of disease requiring therapy.  A variety of other viruses were found, 
but only 1 case of influenza A and 1 case of influenza B.  Two children tested positive for pneumocystis 
pneumonia and one had a positive gene Xpert and positive microscopy for acid fast bacilli (AFB) on 
gastric washing.  Only one of the 26 urine cultures performed grew a bacterial pathogen, and only one 
of the 21 cerebrospinal fluid cultures were positive yielding an Acinetobacter baumanii (hospital 
acquired). (Table 4.8) 
 
Thirteen children (24%) were admitted to the PICU; 92% (12/13) known to be HIV-exposed.   Their 
median age on admission was 96 days (IQR 58 – 229), with a median age at HIV diagnosis of 67 days 
(IQR 44-214).  Just over half (54%, 7/13) were newly diagnosed HIV-infected, while a third (31%, 4/13) 
were previously diagnosed but had not initiated cART.  Two children were previously started on cART 
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(at age 15 and 105 days respectively).  The majority of children admitted to PICU were markedly 
immune suppressed, with 54% (7) having severe immunodeficiency according to WHO CD4 
Immunodeficiency Staging.  The children had high HIV viral loads (median HIV viral load Log 5.6 (IQR 
5.4 – 6.7)) and were underweight for age (median WAZ-score -2.57 (IQR -3.39 - -2.37)).  Pneumonia 
was the principal reason for admission (77%).  Three children in this group died (23%) but PICU 
admission was not predictive of death in the cohort. (Table 4.9) 
 
4.3.4 Access to therapy (Table 4.4, 4.5, 4.6 & Figure 4.2) 
 
The median time from HIV diagnosis to cART initiation was 9 days (IQR 5-30) in children with known 
HIV-exposure risk versus 5 days (IQR 2-8) in those with unknown exposure risk, p=0.039.  There was a 
statistically significant difference in the duration from diagnosis to cART initiation between the groups:  
children initiating therapy as outpatients started therapy at a median of 33 days (IQR 28-63) after the 
first positive PCR, while hospitals initiated cART within 8 days (IQR 5-15) of the first positive PCR, 
p=0.005.  Twenty children initiated therapy prior to enrolment of whom 5 were lost to follow up.  
There were no risk factors identified that predicted child default of treatment. (Table 4.6) 
 
4.3.5 Outcomes (Table 4.7, 4.10) 
 
Seven children (13%) died in hospital.  These children were older [median age 350 days (IQR 68-511)], 
and diagnosed later [median 200 days (IQR 43-335)].  They died after a median of 30 days in hospital, 
53 days after their HIV diagnosis and 33 days on cART.  Three children were previously diagnosed and 
not on cART at hospitalization:  2 never started cART and one defaulted.  All but one child (who died 
prior to re-initiation of previously defaulted cART) were started on treatment during admission. 
 
Children who died tended to be severely underweight-for-age [median WAZ-score -3.3 (IQR -5.45 to -
2.93), and although they had a low median CD4% of 22.9% (IQR 20.5 – 29.3) and high viral loads 
[median log 6.2 (5.6 - 6.5)], these were not significantly different from children who survived. 
 
Pneumonia was the most commonly noted cause of death (n=4, 31%) with concomitant severe acute 
malnutrition as a secondary contributor (n=6, 46%).  Three (43%) of the children who died were 
admitted to PICU for a median duration of 27 days (IQR 4 – 39).  Median duration of hospitalization 
was 30 days (IQR 13 – 54).  There were no factors that predicted deaths in this study.  
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HIV infection was associated with long hospitalization, the median duration was 17 days (IQR 10-
31days), similar in those with known (23 [IQR 12 – 30.5] days) versus unknown exposure-risk (15.5 
[IQR 10 – 32.3] days), p=0.67. (Table 4.7) 
 
 
 
Table 4.5: HIV diagnosis and treatment initiation for children with known HIV-exposure risk 
 
All children with known HIV-
exposure risk 
(N=46) 
Diagnosed in Primary Health 
Care Clinic 
(N=10, 22%) 
Hospital Diagnosed 
(N= 36, 78%)  
n(%) Days Median(IQR) n(%) Days Median(IQR) n(%) Days Median(IQR) p 
Age at HIV diagnosis   54 (3-106)  49.5 (42-93)  54 (2.5-107.5) 0.989 
     Diagnosed by 28 days  14 (30) 0.5 (0-3) 1 (10)  1  13 (36) 1 (0-3)  
     Diagnosed by 42 days  18 (39) 2 (0-19) 4 (40) 41 (20-42) 14 (39) 1.5 (0-3)  
     Diagnosed by 98 days 33 (72) 42 (1.5-56.5) 8 (80) 42.5 (41-56.5) 25 (69) 19 (0.5-57.5)  
     Diagnosed by 180 days  39 (84) 46 (2-91) 9 (90) 43 (41-75) 30 (83) 46.5 (2-91)  
Time from diagnosis to cART initiation   9 (5-30)  32.5 (28-63)  8 (5-14.5) 0.005 
Time to cART initiation by diagnosis age 
      28 days 14 (30) 5 (4-8) 1 (10) 2 13 (36) 5 (4.5-8.5)  
      42 days/6 weeks 18 (39) 6.5 (5-17) 4 (40) 31.5 (16-69) 14 (39) 5.5 (5-8)  
      98 days/ 14 weeks 33 (72) 8 (5-30) 8 (80) 32.5 (29-81) 25 (69) 7 (5-14)  
      180 days/ 6 months 39 (84) 9 (5-30) 9 (90) 33 (29-84) 30 (83) 7.5 (5-14)  
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, IQR – Interquartile range 
 
 
Table 4.6: Children initiated on cART prior to admission 
 All on previous cART (N = 20) 
On cART, in care 
(N=15) 
Defaulted cART 
(N=5) P  
HIV diagnosis age in days  median(IQR) 48 (3 – 83) 56 (2-91) 42 (2 – 68) 0.432 
Diagnosed in Hospital n(%) 13 (65) 11 (73) 2 (40) 0.176 
Time to cART initiation in days median(IQR) 14 (5 – 30) 8 (5-30) 28 (12 – 122) 0.115 
Maternal cART and care default at any time 
prior to child admission n(%) 9 (45) 
6 (40) 
Additional 3 moms never on cART 3 (60) 0.436 
Immunization UTD n(%) 12 (60) 9 (60) 3 (60) 1 
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, IQR – Interquartile range, UTD – Up to date 
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Figure 4.2:  Median age at HIV diagnosis, cART initiation and admission to Tygerberg Hospital 
by HIV-exposure risk knowledge and timing 
 
 
 
 
 
 
. 
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Table 4.7:  Clinical profile of HIV-infected children at enrolment  
 
 
 
All Children 
(N=55) 
Known HIV-Exposure Risk 
(N=46) 
Unknown HIV-Exposure Risk 
(N=9) P  
N/n  N/n  N/n   
Age on admission in days  median(IQR)  174 (90-381)  138 (68 – 382)  282 (180 – 389) <0.001 
Diagnosed during current admission  n(%)  25 (46%)  17 (37)  8 (89)  
Admission weight in gram  median(IQR)  5282 (2900 - 6215)  5236 (2800 - 6129)  6000 (3815 - 6543) 0.562 
Weight-for-Age Z-score  median(IQR)  -2.6 (-4.0 to -1.9)  -2.4 (-4.1 to -1.8)  -3.4 (-4.2 to -2.3) 0.228 
WHO Stage  III + IV n(%)  44 (80)  36 (78)  8 (89) 0.195 
Latest CD4 %   median(IQR) 49*  42* 27.7 7* 24.7 0.731 
 WHO CD4% Immunodeficiency Staging    n(%) 49*  42*  7*   
       Mild immunodeficiency  
             (≤11 months: 30-35%; 12-35 months: 25-30%) 
 6 (12)  4 (10)  2 (29)  
       Advanced Immunodeficiency 
             (≤11 months: 25-29%; 12-35months: 20-24%) 
 9 (18)  7 (17)  2 (29)  
       Severe immunodeficiency 
             (≤11 months: <25%; 12-35 months: <20%) 
 17 (35)  15 (36)  2 (29)  
Latest HIV viral load log median(IQR) 50* 5.5 (4.1 – 6.3) 42* 5.4 (3.9 – 6.2) 8* 6.3 (5 – 6.7) 0.095 
          cART prior, in Care 14 3.9 (2.2 – 5.4) 14 3.9 (2.2 – 5.4)    
          cART prior, not in Care 5 5.9 (5.4 – 6.7) 5 5.9 (5.4 – 6.7)    
          Previously Diagnosed, no cART 9 6.2 (5.2 – 6.6) 8 6 (5.2 – 6.5) 1 6.7  
          Newly Diagnosed 22 5.5 (4.2 – 6.4) 15 5.4 (4.2 – 6) 7 6.2 (4.1 – 6.7)  
Latest Viral load LDL n(%) 50* 3 (6) 42* 3 (7) 8*   
Most common diagnoses n(%)        
       Pneumonia  25 (45)  22 (48)  3 (33) 0.425 
       Gastroenteritis  20 (36)  17 (37)  3 (33) 0.836 
       Severe acute malnutrition  22 (40)  17 (37)  5 (56) 0.191 
      Tuberculosis   10 (18)  8 (17)  2 (22) 0.731 
Admitted to ICU  n(%)  14 (25)  13 (28)  1 (11) 0.280 
ICU admission duration in days median(IQR) 14* 8 (4.8-22.5) 13* 8 (.5 – 18.5) 1* 21 0.122 
Duration of hospital admission in days  median(IQR)  17 (10-31)  15.5 (10 – 32.3)  23 (12 – 30.5) 0.674 
Died n(%)  7 (13)  5 (11)  2 (22) 0.321 
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, ICU – Intensive Care Unit, IQR – Interquartile range, 
LDL – Lower than detectable limit, WHO – World Health Organization 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
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Table 4.8:  Investigations done and organisms found 
Blood cultures 
 Total Number Number of patients tested 
Blood culture done 83 37 
Blood culture positive 10 6 
            MSSA 2 2 
            MRSA 2 1 
            ESBL Klebsiella pneumoniae 1 1 
            E coli 1 1 
            Serratia Marcescens 1 1 
            Enterobacter cloacae 2 1 
            Candida Albicans 1 1 
Respiratory viral panel on NPA or Tracheal aspirate 
 Total Number Number of patients tested 
NPA/TA done 43 22 
Respiratory viral panel positive 31 17 
         CMV 24 12 
              Serum CMV VL done 25 18 
               1st VL positive           Log <3 1  
                                           Log 3-5 9  
                                           Log >5 5  
         Adenovirus 2  
         RSV 3  
         Parainfluenza 2  
         Influenza A 1  
         Influenza B 1  
         Rhinovirus 4  
         Coronavirus OC43 3  
Bacterial and opportunistic infection on sputum/TA 
 Total Number Number of Patients tested 
Tracheal aspirates done 23 13 
Organisms found   
         ESBL Klebsiella pneumonia 4  
         Pseudomonas aeruginosa 1  
         PJP (15 tests, 11 patients) 2  
TB testing 
 Total Number Number of patients tested 
Gastric washings/sputum 62 31 
    Gene Xpert and TB MCS + 1  
Urine Microscopy, Culture and Sensitivity (MCS) 
 Total Number Number of patients tested 
Urine MCS done 26 18 
Positive culture 1  
             ESBL Klebsiella pneumoniae 1  
Cerebrospinal fluid (CSF) MCS 
 Total Number Number of patients tested 
 CSF done 21 17 
Positive culture 1  
             Acinetobacter baumanii 1  
CMV – Cytomegalovirus, CSF – cerebrospinal fluid, E coli – Escherichia coli, ESBL – Extended spectrum beta-
lactamases, MCS – Microscopy, culture and sensitivity, MRSA - Methicillin-resistant Staphylococcus aureus, 
MSSA - Methicillin-sensitive Staphylococcus aureus, NPA – nasopharyngeal aspirate, PJP – pneumocystis jirovecii 
pneumonia, RSV – Respiratory syncytial virus, TA – Tracheal aspirate, TB – Tuberculosis 
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Table 4.9:  Profile of children by PICU admission status 
 
All Children 
(N=55) 
PICU admission 
(N=13,24%) 
No PICU admission 
(N=42,76%) P 
N/n  N/n  N/n   
Male  n(%)  33 (60)  5 (39)  28 (67) 0.070 
Known risk n(%)  46 (84)  12 (92)  34 (81) 0.334 
Age on admission (days) Median (IQR)  174 (90-381)  96 (58 - 228.5)  194.5 (108 – 389) 0.076 
Age at HIV diagnosis (days) Median (IQR)  59 (6-184)  67 (44 - 213.5)  57.5 (3 - 184) 0.476 
Time from HIV diagnosis to cART initiation (days)  
Median (IQR)  8 (5-27)  9 (4.5 - 30)  8 (5 – 17) 0.751 
Child cART Status n(%)       0.243 
       Newly diagnosed  25 (45)  7 (54)  18 (43)  
        Prior cART, In Care  15 (27)  2 (15)  13 (31)  
       Prior cART, not in care  5 (9)    5 (12)  
       Previously Diagnosed, No cART  10 (18)  4 (31)  6 (14)  
CD4 Latest (%)  median(IQR) 49* 23.7 (17.9 – 36.3)  23.7 (16.4 – 43.4) 36* 27.7 (20.6 – 36.3) 0.803 
WHO CD4% Immunodeficiency Staging    n(%) 49*     36*    
     Mild immunodeficiency  
          (≤11 months: 30-35%; 12-35 months: 25-30%)  6 (12)  1 (8)  5 (14)  
     Advanced Immunodeficiency 
          (≤11 months: 25-29%; 12-35months: 20-24%)  9 (20)  1 (8)  8 (22)  
     Severe immunodeficiency 
         (≤11 months: <25%; 12-35 months: <20%)  17 (35)  7 (54)  10 (28)  
Viral load (log) latest Median (IQR) 50* 5.5 (4.1 – 6.3) 12* 5.6 (5.4 - 6.7) 38* 5.3 (3.8 – 6.2) 0.053 
Viral load LDL  n(%) 50* 3 (6) 12* 0 38* 3 (8)  
Viral load <1000 copies/ml  n(%) 50* 5 (10) 12* 0 38* 5 (13)  
Weight-for-Age Z score Median (IQR)  -2.6 (-4.0 to -1.9)  -2.57 (-3.39 to -2.37)  -2.58 (-4.34 to -1.55) 1 
Diagnosis n(%)        
                   Pneumonia  25 (45)  10 (77)  15 (36)  
                   Gastroenteritis  20 (36)  2 (15)  18 (43)  
                   Severe acute malnutrition  22 (40)  5 (38)  17 (40)  
                   Tuberculosis  10 (18)  3 (23)  7 (17)  
ICU duration Median (IQR)    8 (5.5 - 24)    
Hospitalization duration in days  median(IQR)  17 (10 – 31)  32 (16 – 55)  14 (9 – 26) <0.005 
Deaths  n(%)  7 (13)  3 (23)  4 (10) 0.200 
All LDL on cART, 1 <1000 newly diagnosed 
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, PICU – Paediatric Intensive Care Unit, IQR – Interquartile range, 
LDL – Lower than detectable limit, WHO – World Health Organization 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
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Table 4.10:  Comparing children that died with those who survived 
 
All Children 
(N=55) 
Deaths 
(N=7,13%) 
Survived 
(N=48,87%) P 
N/n  N/n  N/n   
Male  n(%)  33 (60)  2 (29)  31 (65) 0.070 
Known risk  n(%)  46 (84)  5 (71)  41 (85) 0.350 
Age on admission (days)  Median(IQR)  174 (90-381)  350 (68 - 511)  154 (93 – 370) 0.235 
Age at HIV diagnosis (days) Median(IQR)  59 (6-184)  200 (43 - 335)  57 (6 – 136) 0.165 
Time from HIV diagnosis to cART initiation (days) 
Median(IQR)  8 (5-27)  10 (7 - 28)  8 (5 – 22) 0.419 
Child cART Status n(%)       0.370 
       Newly diagnosed  25 (45)  4 (57)  21 (44)  
       Prior cART, In Care  15 (27)  0  15 (31)  
       Prior cART, not in care  5 (9)  1 (14)  4 (8)  
       Previously Diagnosed, No cART  10 (18)  2 (29)  8 (17)  
CD4 % Latest  median(IQR) 49* 23.7 (17.9 – 36.3) 6* 22.9 (20.5 – 29.3) 43* 28.2 (17.7 – 37.2) 0.784 
 WHO CD4% Immunodeficiency Staging    n(%) 49*   6*  43*    
       Mild immunodeficiency  
                  (≤11 months: 30-35%; 12-35 months: 25-30%)  6 (12)  1 (17)  5 (12)  
       Advanced Immunodeficiency 
                  (≤11 months: 25-29%; 12-35months: 20-24%)  9 (20)  1 (17)  8 (19)  
       Severe immunodeficiency 
                  (≤11 months: <25%; 12-35 months: <20%)  17 (35)  3 (50)  14 (33)  
Viral load (log) latest Median(IQR) 50* 5.5 (4.1 – 6.3)  6.2 (5.6 - 6.5) 43* 5.4 (3.9 – 6.3) 0.096 
Weight-for-Age Z -core Median (IQR)  -2.6 (-4.0 to -1.9)  -3.3 (-5.26 to -2.93)  -2.43 (-3.88 to -1.88) 0.123 
Diagnosis n(%)        
                        Pneumonia  25 (45)  4 (31)  21 (44)  
                        Gastroenteritis  20 (36)  0  20 (42)  
                         Severe Acute Malnutrition  22 (40)  6 (46)  16 (33)  
                        Tuberculosis  10 (18)  1 (8)  9 (19)  
ICU admission  n(%)  14 (25)  3 (43)  11 (23) 0.258 
ICU duration  Median(IQR) 14* 8 (4.8-22.5) 3* 27 (4 – 39) 11* 8 (5 – 10) 0.390 
Hospitalization duration (days)  Median(IQR)  17 (10-31)  30 (13 – 54)  14 (10 – 27) 0.136 
Time from HIV Diagnosis to death (days) Median(IQR)    53 (34 – 104)    
Time from cART initiation until death (days) 
Median(IQR)    33.5 (17 – 47)    
cART – combination antiretroviral therapy, HIV – Human immunodeficiency virus, ICU – Intensive Care Unit, IQR – Interquartile range, 
LDL – Lower than detectable limit, WHO – World Health Organization 
*  Discrepancy in denominator value in concordance with availability of data for the specific parameter 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 39 
 
4.4 ROAD-TO-HEALTH BOOKLET AND VACCINATION STATUS 
 
Table 4.11:  Road-to-Health Booklet HIV-related data completion and vaccination status review 
 
All Cases 
Known Risk 
Unknown Risk 
All Known Risk Mother Diagnosed Prior to Pregnancy 
Mother Diagnosed 
during Pregnancy 
Assessed 
(N) 
Complete 
n (%) 
Assessed 
(N) 
Complete 
n (%) 
Assessed 
(N) 
Complete 
n (%) 
Assessed 
(N) 
Complete 
n (%) 
Assessed 
(N) 
Complete 
n (%) 
RtHB present 48 ∞ 46 (96) 40 39 (98) 28 27 (96) 12 12 (100) 8 7 (88) 
HIV-Related pages completed 46 8 (17) 39 7 (18) 27 4 (15) 12 3 (25) 7 1 (14) 
6-week PCR done* 31 19 (61) 31 19 (61) 22 14 (64) 9 5 (56)   
6-week PCR result documented* 19 15 (79) 19 15 (79) 14 10 (71) 5 5 (100)   
Bactrim Prophylaxis at 6 weeks* 29 15 (52) 29 15 (52) 21 11 (52) 8 4 (50)   
Appropriately vaccinated for age 46 29 (63) 39 24 (62) 27 16 (59) 12 8 (67) 7 5 (71) 
HIV – Human immunodeficiency virus, PCR – polymerase chain reaction, RtHB – Road-to-Health Booklet 
∞ 7 of the 55 enrolled children still in neonatal period and with no RtHB issued excluded 
* Only RtHBs of children older than 6 weeks of age were assessed 
Denominator value reported dependent on availability of data for the specific parameter  
 
Seven of the 55 children (12.7%) were in the neonatal service and had not yet been issued RtHBs.  Of 
the remaining 48 children, 46 (96%) had RtHBs available for review.  The median age of these 46 
children was 6.4 (IQR 3.6 – 12.7) months:  Known risk 5.7 (IQR 3.2 – 12.8) and unknown exposure 9.3 
(IQR 6.4 – 12.1) months, p=0.343. 
 
Of the 39 children, whose mothers had known antenatal HIV-infection, the HIV-pages were fully age-
appropriately completed in 7 (18%).  Performance of diagnostic PCRs in children older than 6 weeks 
was noted in 19/31 children (61%) and results documented in 15/19 (79%).  Initiation of co-
trimoxazole at 6-week age was documented in 15/29 (52%).  Of the 8 HIV-infected children without 
known antenatal HIV-exposure, 7 (88%) had RtHBs available; 1 (14%) had appropriate documentation 
of maternal HIV status during pregnancy. 
 
The age-appropriate vaccination uptake was 62% (24/39) in antenatally known-risk and 71% (5/7) in 
children identified postpartum, p=0.801. 
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5.  DISCUSSION 
5.1 GENERAL FINDINGS WITH REGARDS CARE OF HIV-INFECTED WOMEN 
 
South Africa has a 94% uptake of HIV-testing in pregnant women(23) and pMTCT programmes in 
approximately 98% of healthcare facilities.(12)  Reviews of the HIV infection outcomes of perinatally 
exposed infants report a transmission rate of 1.5%.(21) 
 
In previous local and international studies, failure to recognise the exposure-risk, and therefore 
absence of preventative ART, was identified as the major driver of HIV-infection in the era of effective 
HIV prevention.  This was noted even prior to all mothers accessing cART during pregnancy and before 
data on the importance of treating all infected adults regardless of clinical state and CD4 count had 
emerged.  In contrast however, in our review, the minority (16%) of patients were not identified during 
the antenatal period.  We identified poor antenatal clinic attendance and cART interruption in women 
aware of their HIV-status prior to pregnancy and failure of women on cART prior to pregnancy to 
achieve viral suppression as the driver of newly infected infants.  For women identified during 
pregnancy, the short duration on cART was an important factor to consider as the median time on 
cART at delivery was 0.5 months (IQR 1 – 3), an insufficient time to achieve viral suppression. 
 
Furthermore, although we were unable to verify this, 9 mothers reported that they were aware of 
their HIV-status during pregnancy and attended antenatal clinic, but did not receive any prevention.  
These women all attended antenatal care for the first time after 28 weeks, but we did not collect data 
on the exact gestation at which they presented.  We could also not verify access to AZT antenatally 
and intrapartum NVP, TDF/FTC and AZT, nor were there any indication of prevention in the RtHB of 
their infants.  However, we noted that women who did not access cART were delivering babies at term 
in the majority of cases. 
 
With regards to overall antenatal clinic attendance, 2014 data suggests that in South Africa 7.1 % and 
in the Western Cape 14.7% of pregnant women did not seek antenatal care.(18)  Although this is a 
bias sample, in this study antenatal clinic attendance was unacceptably poor, especially in women 
aware of their HIV-status and with prior cART exposure.  We found a combined ANC attendance of 
76% (42/55):  Known HIV-exposure risk cases 35/46 (76%) and unknown HIV-exposure risk cases 7/9 
(78%).  Only 20 of the 31 women (65%) with known HIV-infection prior to the index pregnancy 
attended antenatal clinic.  This is in contrast to a case-control study by Mnyani et al. conducted in 
Johannesburg from Nov 2010 to May 2012 where 85.7% of women with infected infants attended 
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antenatal care.(64)  Also, in Johannesburg, in a five facility operational follow-up study of HIV-infected 
children under 2 years, Technau et al. documented that 96% of mothers attended antenatal clinic at 
least once.(65)  In keeping with data documented in Gauteng (that found a median gestation at ANC 
presentation of 24 weeks (IQR 16 - 28)(65)), and Kwazulu-Natal (where a 25% booking rate after 28 
weeks gestation and 63% between 13 – 27 weeks was documented(66)), women in our study who 
attended antenatal clinic tended to present late for antenatal care, with only 6.5% (3/46) presenting 
prior to 14 weeks’ gestation.  The reasons for this lack of early presentation are complex and may 
include maternal perceptions of the role of the antenatal service, as well as the healthcare system not 
actively encouraging early pregnancy attendance.  Interestingly, all women who attended antenatal 
care but did not start therapy presented after 28 weeks’ gestation. 
 
Longer treatment duration prior to delivery with effective control of HIV-viraemia, is essential to 
prevent in-utero and intrapartum transmission, but also makes breastfeeding safer.(64)  Where 
women in our study initiated cART during pregnancy, the duration on therapy was not long enough to 
achieve viral suppression, even though few infants were very premature.  Mothers diagnosed during 
pregnancy tended to deliver late preterm infants [median of 35 weeks’ gestation (IQR 33-38)].  Late 
premature delivery and low birthweight is common in South Africa and other developing countries, 
even in infants without HIV-exposure, as corroborated by  the 2010 global estimated low birthweight 
rate of 15.5% (96% of which occurred in developing countries) and  preterm delivery rate of  
11.1%.(67) 
 
In infants of HIV-infected mothers, high rates of late prematurity are also reported in mothers on cART 
prior to pregnancy and those who initiate cART during pregnancy.  The causes are complex and 
multifactorial. Cohort studies from other African countries also report late prematurity and low 
birthweight in HIV-infected infants, both of mothers on cART prior to pregnancy, mothers initiating 
cART during pregnancy and mothers not on cART.(68,69) 
 
The women in this study had a median age of 28 years (IQR 24 – 31) at delivery of the index pregnancy.  
Of note is the absence of teenage pregnancy in this cohort, as failure of adolescent girls to attend 
antenatal care and adhere to therapy, in this sub-group of pregnant women, is a well-known 
phenomenon, but cannot be implicated in the poor health-seeking behaviour in the majority of 
women in this cohort.(70,71)  Our higher maternal age is in keeping with the median ages of women 
enrolled in other pMTCT and EID trials and studies in South Africa.  In these studies women ranged 
from 27 - 28 years of age, and in the majority of cases were not primigravida.(64–66) 
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Mothers were markedly immune-suppressed during pregnancy, a further risk factor for transmission, 
as well as when their children were enrolled.  Forty-one of the 46 (89%) women known to be HIV-
infected antenatally, had a CD4 count done during pregnancy or in the immediate postpartum period, 
88% (36/41) having CD4 counts less than 500 cells/mm3 of which 14 (34%) had a CD4 count less than 
200 cells/mm3.  This is comparable to data from Kwazulu-Natal that showed 27% of HIV-infected 
pregnant women having a CD4 count of less than 200 cells/mm3 and 86% less than 500 cells/mm3.(66)   
Although CD4 counts are no longer needed to initiate cART in pregnancy, they are still part of care and 
the test is used as the basis for screening for cryptococcal infection.(12)  Low CD4 counts are a known 
risk factor for transmission, even with access to pMTCT.(69)  
 
We noted high rates of infectious co-morbidity, including tuberculosis and syphilis.  This trifecta of late 
presentation, advanced disease with low CD4 cell count and high HIV viral load with additional co-
morbidities may indicate that these women were at higher risk of pMTCT failure.  However, we do not 
have denominator data that will allow us to further describe these specific risk factors. 
 
At the time the child was enrolled, 22 (48%) of the mothers were in care, and 15 (33%) indicated that 
they were not currently taking a previously initiated cART regimen and were not attending clinical care 
for their own health.  The high postpartum loss to follow-up in our cohort is not unique and is well 
documented in local and international settings.  An earlier study from Cape Town showed a  loss to 
follow-up (LTFU) of 32% (72), while in Malawi, the first country to start all pregnant women on cART 
and keep them on cART postpartum, up to 30% loss to follow-up is reported.(71)  In a USA cohort, 
only 31% of women initiating cART during pregnancy were virally suppressed (HIV VL ≤200 copies/ml) 
and in care by one year postpartum, while data from the UK and Ireland indicated that 27% of women 
who initiated cART during pregnancy were not virally suppressed (HIV VL >200 copies/ml) by a year 
postpartum.(73) 
 
In order to promote not just cART-initiation, but also retention in care for both mothers and their 
infants, maternal-child-health units with integrated antenatal and postnatal care, pMTCT, cART care, 
as well as routine healthy child visits may improve retention outcome.  Eighteen women in this cohort, 
not on cART at conception, received antenatal care and cART care at the same facility, 6 of them 
defaulted care.  Not receiving care at the same facility did not predict defaulting in this group.  
Operational research in Cape Town showed that, in women randomized to receive either postpartum 
standard of care or otherwise being managed in the well-baby service, those getting care in the well-
baby service had improved duration of breastfeeding (3 months to 9 months) and 77% of the mothers 
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remained in care and were suppressed (as a combined end-point) vs 56% of mothers in the standard 
of care arm, <p=0.001.(74)  Though this is a substantial improvement, there still remains significant 
loss to care, in routine services. 
 
Postpartum contraception uptake was very low in this cohort, only 55%, leading to the risk of further 
pregnancies and ongoing future risk of HIV transmission for women presenting late to ANC or not in 
care.  Mothers also had low levels of knowledge about partner status and disclosure-status is still 
unacceptably low. 
 
5.2 GENERAL FINDINGS WITH REGARDS CARE OF HIV-INFECTED CHILDREN 
 
The median birthweight of infants born to mothers known with HIV-infection was less than 2500g.  
This included those born to mothers with HIV diagnosed prior to pregnancy, despite their median 
gestation being slightly higher.  High rates of low birthweight are reported in this context.(46)  Notably 
infants born to mothers not identified in pregnancy were also small (median BW 2595g (IQR 2180 - 
2830). 
 
The uptake of infant prophylaxis was good, with 93% of infants accessing antiretroviral drug 
prevention. 
 
Mothers diagnosed during pregnancy chose to exclusively breastfeed in 87% of cases, in contrast to 
52% of previously diagnosed mothers choosing exclusive formula feeding from birth.  We were not 
able to explore the reasons for the low uptake of breastfeeding in these mothers or whether the 
feeding choice was adhered too.  Mothers with prior engagement with the healthcare system may 
have been exposed to prior guidance on formula feeding, and/or understand their inability to adhere 
to medication with subsequent fear of HIV-transmission to the infant.  These feeding trends are similar 
to those of pMTCT programmatic failure research in Johannesburg by Technau et al., where children 
were more likely to be exclusively breastfed during the first 6 months in mothers diagnosed during 
pregnancy (45%) or postpartum (56%), than if they were diagnosed prior to the index pregnancy 
(27%).(65) 
 
The median age at diagnosis of HIV in infants with known exposure risk was similar to that of studies 
from Johannesburg:  49 days for babies born to mothers diagnosed prior to pregnancy and 77 days if 
diagnosed during pregnancy in data by Technau et al. (65), and a mean of 63 days in data by Mnyani 
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et al. (64).  Fourteen (30%) of these infants were diagnosed in the neonatal period, with 72% (33/46) 
diagnosed prior to 3 months of age.  Of note is the high number of children diagnosed during 
hospitalization,  similar to routine data from both the CHER sites that highlighted the very rapid 
progression to severe disease in infants identified as infected at a young age.(10)  This rapid 
progression emphasizes the need to ensure early testing and access to cART. 
Despite being clinically symptomatic, children with unknown HIV-risk were older.  We did not explore 
possible reasons for a delay in their testing.  At enrolment children were symptomatic and 27% of 
children with an available CD4 count (13/49) were severely immune suppressed.  The province has 
since implemented birth PCR and this may again facilitate access to care.  Though the majority of 
infants identified were young, the importance of ongoing follow-up is clear from the number of 
children diagnosed after 6 months of age with an initially negative PCR. 
 
Despite 30 children (55%, N=55, one child with unknown exposure risk diagnosed prior to current 
admission, but not started on cART, all other unknown risk children were newly diagnosed) being 
diagnosed prior to admission to Tygerberg Hospital, only 20 initiated cART, of which 5 defaulted care 
prior to admission.  Of the 15 still in care, 5 were virally suppressed (with HIV VL < 400 copies/ml). 
 
The median age at cART initiation in our cohort was 76 days (IQR 20-178) in children with known 
exposure risk, with time from diagnosis to cART initiation being 9 days (IQR 5-30).  This is similar to 
Johannesburg data where cART was initiated at 76 days of age and within 12.6 days of diagnosis in the 
Mnyani et al. cohort(64) and at 112 days, but only within 71 days of diagnosis in the Lillian et al. 
cohort.(75)  Children diagnosed in the clinic setting, despite statistically insignificant difference in 
diagnosis age [50 days (IQR 42 – 93) in clinic versus 54 days (IQR 3 – 108) in hospital, p = 0.989], took 
33 days (IQR 28 – 63) to be initiated on cART versus 8 days (IQR 5-15) in hospitalized children, p = 
0.005.  Follow-up and rapid initiation systems in primary care will need to be strengthened in order to 
facilitate rapid access to cART once infants are infected so that mortality and morbidity can be 
prevented. 
 
Even though marked progress has been made in the early identification of HIV-infected children from 
within the pMTCT programme, including the introduction of the birth PCR, we are still too late in 
identifying these children prior to them presenting with severe disease.  Furthermore, once identified 
and initial linkage to care, initiation on treatment and retention in care is a problem.  Interventions 
need to be put in place along all these steps in the treatment continuum to ensure maximal 
effectiveness.  They may include, the linking of babies to care by means of ward-based outreach teams 
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and early social support intervention where needed; the linking of infants to a national/provincial data 
system so that information can be easily accessed electronically, as well as the use of specialized RtHB 
identifier coding for all NHLS blood tests to ensure easy access to results.  Retention in care can be 
addressed by maternal counselling and education, as well as addressing issues such as stigma and fear, 
lack of partner disclosure and support, as well as poor or difficult access to health care services.(49) 
 
5.2.1 Clinical condition during admission: 
 
Children from this cohort most commonly suffered from Pneumonia (45%, 25/55), gastroenteritis 
(36%, 20/55) and malnutrition (40%, 22/55).  Tuberculosis, mostly pulmonary, was diagnosed in 10 
children (18%).  High rates of pulmonary tuberculosis are well documented in this setting.  Walters et 
al, in a cohort review at the same facility reported that the number of TB cases per 100 patient years 
were 53.3 during the 9 months prior to HAART initiation, and 6.4 during post HAART follow-up [odds 
ratio (OR) 16.6; 95% confidence interval (CI) 12.5–22.4].(76)   
There were few confirmed cases of PJP (2), no pneumococcal infections and only 2 cases of influenza.  
However, other viral infections, particularly CMV, were found in a number of children.  Confirming 
CMV disease is complex, but high viraemia supports that CMV is an important pathogen in these 
children.(56)  Access to Ganciclovir is limited and if we want to make further gains in the early mortality 
of HIV-infected children, this needs attention. 
 Of particular concern is the high mortality (13%), need for intensive care (25% of children) and long 
duration of hospitalization.  The main causes of death, poor nutritional state and prolonged 
hospitalization of deceased children in our cohort were similar to those identified by Child PIP in the 
2012-2013 Saving Children Report.(63) 
 
5.2.2 Road-to-Health Booklet and vaccination status 
 
Review of this important tool showed 2 major concerns: 
 
Firstly, health care workers are not completing the document fully.  This is congruent with findings 
from Kalafong hospital, Tswane, South Africa where inadequate reporting of infant testing on the RtHB 
occurred in 74% of cases.(77)  National cross-sectional survey data from 2011 by Woldensebet et al. 
also reiterates these findings, with only 34% of surveyed RtHBs indicating maternal or child HIV-status 
and only 49% of booklets of infants of self-reported HIV-infected mothers being corroboratively 
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completed.(24)  We know that healthcare workers and mothers may be concerned that the 
documentation of HIV status may lead to inadvertent status disclosure, for instance at day care and 
preschool, however failure to complete this document properly may cause significant delay in care.  It 
is imperative that healthcare workers be trained and guided to comply with the correct completion of 
this very important document, as it has far-reaching medical benefits and implications.  The practice 
of non-completion of the HIV-related pages on maternal request to protect her own status, is 
something that needs to be addressed through advocacy and communicating with mothers. 
 
Secondly, there is poor vaccine uptake in this group of infants, contributing to their already significant 
risk for illness.  We did not explore the reasons for this further, but it may potentially indicate a deeper 
issue in the care of these children, and in conjunction with the data on maternal adherence and 
defaulting of infant cART, may indicate poor maternal health-seeking behaviour.  This trend does not 
only influence vaccination-status, but has far-reaching complications in the health of the woman 
herself, if she does not adhere to her own treatment, as well as her child’s future morbidity and 
possible mortality. 
 
5.2.3 Disclosure of HIV status and support 
 
HIV, despite marked advances in treatment and management, is a complex chronic disease marred by 
its current incurability and the internal and external stigma that surrounds it.  It is imperative that a 
sound support system is available.  Partners especially have a vital role to play, and it is important that 
they too are aware of their HIV status, in order to protect them in cases of discordance, or for them 
to receive treatment when indicated. 
 
Results from this study shows poor levels of knowledge of partner HIV status at only 56%.  The child’s 
status was only disclosed in 79% of cases (26/33), and family and the partner were only involved with 
the child’s care in 65% (17/26) and 59% (16/27) of previously diagnosed cases respectively.   These 
low levels of knowledge of partner-status and the involvement of partners and other family members 
are very concerning.  Partner-involvement and testing is a subject that needs more attention.  
Programmes focusing on testing women together with partners, as well as encourage antenatal 
attendance of men with their partners need to be developed and implemented. 
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6. STRENGTHS AND LIMITATIONS 
 
The fact that HIV-infected children were prospectively enrolled, with a maternal interview and 
questionnaire at the time of enrolment strengthened the data collection, as there was less reliance 
on folder review. 
 
This study is limited by the lack of controls in the form of HIV-exposed HIV non-reactive children less 
than 18 months in order to qualify and quantify the risk factors most influential in causing pMTCT 
failure. 
 
As this study was done in Tygerberg Hospital, a secondary/tertiary centre, with a prominent neonatal 
setting, there may be bias as the study participant profile may not accurately reflect that of the 
drainage population or South Africa as a whole. 
 
Our reliance on patient reports that were not always verifiable through additional sources, was a 
further limitation. 
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7. CONCLUSIONS 
 
This study highlighted that the majority of HIV transmission from mother to child occurs in women 
known to be HIV-infected, but who we are struggling to engage consistently in care.  Prior 
disengagement from cART, no or late antenatal attendance and poor viral suppression rates in women 
on cART are driving transmission in this group.  Patients who have a history of disengagement of care 
and who present late to antenatal clinic may need to receive particularly targeted interventions during 
the pregnancy and postpartum period. 
 
Mothers and their children were poorly retained in care once initiated, which again emphasizes the 
need for a perhaps more personalized approach in pMTCT and subsequent cART treatment 
continuation, incorporating multiple spheres.  This may include interventions like integration of all 
services into Maternal & Child Health (MCH) centres, utilizing social support networks; addressing 
stigma, whether internal or external(21); use of technology and messaging as reminders; partner 
testing and support; reducing unwanted pregnancies through contraception. 
 
Despite children with known HIV-exposure risk being diagnosed at a young age (median 54 days) and 
being timeously initiated on treatment (9 days), the level of morbidity and mortality (13%) is still very 
high.  Most children are being diagnosed in hospital during acute illness episodes, prior to the 
designated outpatient EID point.  Children with unknown HIV exposure risk were diagnosed late 
(median age of 285 days) during hospitalization with marked immunosuppression and concomitant 
malnutrition.  Viral pneumonia and gastroenteritis were the main reasons for admission, with 
tuberculosis also prominent.  These findings highlight the need for early provider initiated testing in 
all symptomatic children irrespective of their HIV-exposure status. 
 
Road-to-Health Booklets, although present in most cases, were poorly completed.  This may be 
indicative of not only a maternal disclosure and stigma issue, but also a further reaching healthcare 
worker and system issue, where the importance and consequences of missed infant HIV infection is 
not fully comprehended.  The poor vaccination uptake in these children indicates the possibility of 
poor health-seeking behaviour in this cohort.  This once again emphasizes the potential need for 
improved and more individualized ways to identify, support and manage these mother-infant pairs in 
order to improve adherence and retention in care. 
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8. FURTHER RESEARCH 
 
Further research is needed along multiple points in the pMTCT continuum.   
 
Topics may include: 
• An exploration of reasons why HIV-infected women do not engage in care.  
• Methods of successfully linking women and children to care and retaining them. 
• Methods to identify and re-admit women who have been lost from the HIV care continuum. 
• Improved identification of HIV-infected but unknown exposure children. 
• Interventions to improve utilization of the RtHB as an important tool in the child HIV 
management. 
• Methods to improve partner testing, disclosure and involvement. 
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9. RECOMMENDATIONS 
 
Despite the high quality, effective pMTCT regimen in place, health system and human factors continue 
to play a major part in failure of prevention of mother-to-child transmission of HIV.  
 
Improvements in voluntary counselling and testing (VCT) and PICT are not enough.  Women who are 
tested need to be started on cART in a timely fashion in conjunction with a dependable, non-
judgemental, trustworthy support system (of health care, community and family origin).  Adherence 
and retention in care are major pressure points that need attention.  
 
We have identified major gaps in the pMTCT continuum that need to be explored further.  Possible 
suggestions for alleviating these problems may include:   One-stop mother-and-child health and HIV-
care, use of cellular reminders/messages, support groups and peer-counsellors, the improved 
involvement of partners/spouses/family members, as well as efforts towards the de-stigmatization of 
HIV in the community. 
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